研究者データベース

遠藤 知之(エンドウ トモユキ)
北海道大学病院 内科
講師

基本情報

所属

  • 北海道大学病院 内科

職名

  • 講師

学位

  • 医学博士(北海道大学大学院医学研究科)

論文上での記載著者名

  • ENDO TOMOYUKI

ホームページURL

J-Global ID

研究分野

  • その他 / その他

研究活動情報

論文

  • Norio Kawamura, Ryoichi Goto, Yasuyuki Koshizuka, Masaaki Watanabe, Tomomi Suzuki, Tomoyuki Endo, Takeshi Kondo, Akinobu Taketomi, Tsuyoshi Shimamura
    Japanese journal of infectious diseases 2020年04月30日 [査読有り][通常論文]
     
    We report the second case of deceased donor liver transplantation in a patient co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in Japan. A 48- year-old patient with hemophilia A was infected with HIV and HCV through a contaminated factor VIII concentrate in his childhood and developed cirrhosis and hepatocellular carcinoma. The patient was on the transplant list for a deceased donor liver. The patient had broad spectrum anti-HLA class I and II antibodies, which may have been due to repeated whole blood transfusions in the past. Catastrophic coagulopathy during the surgery was predicted because of the underlying hemophilic status and severe thrombocytopenia requiring HLA-matched platelet products, which are difficult to obtain quickly. To maintain adequate platelet counts(>5x104/ μl) while waiting liver transplantation, a thrombopoietin receptor agonist and rituximab were administered. During surgery, factor VIII concentrate was administered according to the previously planned protocol. Adequate hemostasis was obtained, and the operation was completed without uncontrollable coagulopathy. The postoperative course was uneventful, and the patient was discharged on postoperative day 41. Detailed planning is required for surgical patients with hemophilia and HIV/HCV cirrhosis, especially for those with a diverse spectrum of anti-HLA antibodies.
  • Souichi Shiratori, Hiroyuki Ohigashi, Shuichiro Takahashi, Takahide Ara, Hideki Goto, Masao Nakagawa, Junichi Sugita, Masahiro Onozawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima
    Annals of hematology 99 3 591 - 598 2020年03月 [査読有り][通常論文]
     
    Although a combination of calcineurin inhibitor and methotrexate (MTX) is used for graft-versus-host disease (GVHD) prophylaxis in umbilical cord blood transplantation (CBT), optimal dose of MTX for CBT remains to be determined.We conducted a retrospective study to evaluate the safety and efficacy of standard-dose MTX (St-MTX, 15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6) and mini-dose MTX (Mini-MTX, 5 mg/m2 on days 1, 3 and 6) for GVHD prophylaxis in patients who underwent single unit CBT against hematological malignancies.Thirty-two and 26 patients received St-MTX and Mini-MTX, respectively. Cumulative incidence of neutrophil engraftment was significantly higher in the Mini-MTX group than in the St-MTX group (88.5% vs 65.6%, P = 0.00448). Cumulative incidences of grade II to IV and grade III to IV of acute graft-versus-host disease (GVHD) were 34.4% and 6.2% in the St-MTX group, and 34.6% and 7.7% in the Mini-MTX group with no statistical significance. One-year non-relapse mortality (NRM) was significantly lower in the Mini-MTX group compared to the St-MTX group (31.2% vs 3.8%, P = 0.00938), whereas relapse rate was not different between the groups. Multivariate analysis also indicated that Mini-MTX significantly improved engraftment (HR, 0.5359; 95% CI, 0.3082 to 0.9318; P = 0.0270) and reduced NRM (HR, 0.117; 95% CI, 0.0151 to 0.9067; P = 0.040).Our study suggests that GVHD prophylaxis using Mini-MTX in CBT is feasible and associated with improvement of engraftment and reduction in NRM.
  • 豊嶋 崇徳
    Biol Blood Marrow Transplant 24 10 1990 - 1996 2018年10月 [査読有り][通常論文]
  • Okada K, Endo T, Hashimoto D, Saga T, Ara T, Ogasawara R, Yasumoto A, Ibata M, Takahata M, Shigematsu A, Kondo T, Muraosa Y, Nomura T, Kanno-Okada H, Hashino S, Tanaka S, Kamei K, Teshima T
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 24 8 660 - 663 2018年08月 [査読有り][通常論文]
  • Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Yoshihisa Kodera, Tadashi Matsushita, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida
    CANCER SCIENCE 108 8 1634 - 1639 2017年08月 [査読有り][通常論文]
     
    The outcomes of cord blood transplantation with non-irradiated reduced-intensity conditioning for hematological malignancies need to be improved because of graft failure and delayed engraftment. Intrabone infusion of cord blood cells has the potential to resolve the problems. In this phase II study, 21 adult patients with hematological malignancy received intrabone transplantation of serological HLA-A, B, and DR >= 4/6 matched single cord blood with a median number of cryopreserved total nucleated cells of 2.7 x 10(7) /kg (range, 2.0-4.9 x 10(7) /kg) following non-irradiated fludarabine-based reduced-intensity conditioning. Short-term methotrexate and tacrolimus were given as graft-versus-host disease prophylaxis, and granulocyte colony-stimulating factor was given after transplantation. No severe adverse events related to intrabone injection were observed. The cumulative incidences of neutrophils >= 0.5 x 10(9) /L, reticulocytes >= 1%, and platelets >= 20 x 10(9) /L recoveries were 76.2%, 71.4%, and 76.2%, respectively, with median time to recoveries of 17, 28, and 32 days after transplantation, respectively. The probability of survival with neutrophil engraftment on day 60 was 71.4%, and overall survival at 1 year after transplantation was 52.4%. The incidences of grade II-IV and III-IV acute graft-versus-host disease were 44% and 19%, respectively, with no cases of chronic graft-versus-host disease. The present study showed the safety of direct intrabone infusion of cord blood. Further analysis is required to confirm the efficacy of intrabone single cord blood transplantation with non-irradiated reduced-intensity conditioning for adult patients with hematological malignancy. This study was registered with UMIN-CTR, number 000000865.
  • Minoru Kanaya, Tomoyuki Endo, Daigo Hashimoto, Shogo Endo, Ryo Takemura, Kohei Okada, Kanako C. Hatanaka, Yoshihiro Matsuno, Takanori Teshima
    INTERNATIONAL JOURNAL OF HEMATOLOGY 106 2 147 - 148 2017年08月 [査読有り][通常論文]
  • Takahiro Tateno, Masahiro Onozawa, Junichi Hashiguchi, Takashi Ishio, Sayaka Yuzawa, Satomi Matsuoka, Mizuha Kosugi-Kanaya, Kohei Okada, Souichi Shiratori, Hideki Goto, Taichi Kimura, Junichi Sugita, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Shinya Tanaka, Satoshi Hashino, Takanori Teshima
    TRANSPLANT INFECTIOUS DISEASE 19 4 2017年08月 [査読有り][通常論文]
     
    We herein report a patient who had disseminated toxoplasmosis after hematopoietic stem cell transplantation showing atypical clinical presentation and neuroimaging. Parkinsonism symptoms such as muscle rigidity, bradykinesia, tremor, and postural instability were initial manifestations. Magnetic resonance imaging showed diffuse symmetrical lesions of bilateral basal ganglia lacking ringed enhancement. Post-mortem analysis revealed multiple tachyzoites of Toxoplasma gondii in the basal ganglia, mid brain, cerebellum, and cardiac muscle.
  • Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Yoshihisa Kodera, Tadashi Matsushita, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida
    Cancer science 108 8 1634 - 1639 2017年08月 [査読有り][通常論文]
     
    The outcomes of cord blood transplantation with non-irradiated reduced-intensity conditioning for hematological malignancies need to be improved because of graft failure and delayed engraftment. Intrabone infusion of cord blood cells has the potential to resolve the problems. In this phase II study, 21 adult patients with hematological malignancy received intrabone transplantation of serological HLA-A, B, and DR ≥4/6 matched single cord blood with a median number of cryopreserved total nucleated cells of 2.7 × 107 /kg (range, 2.0-4.9 × 107 /kg) following non-irradiated fludarabine-based reduced-intensity conditioning. Short-term methotrexate and tacrolimus were given as graft-versus-host disease prophylaxis, and granulocyte colony-stimulating factor was given after transplantation. No severe adverse events related to intrabone injection were observed. The cumulative incidences of neutrophils ≥0.5 × 109 /L, reticulocytes ≥1%, and platelets ≥20 × 109 /L recoveries were 76.2%, 71.4%, and 76.2%, respectively, with median time to recoveries of 17, 28, and 32 days after transplantation, respectively. The probability of survival with neutrophil engraftment on day 60 was 71.4%, and overall survival at 1 year after transplantation was 52.4%. The incidences of grade II-IV and III-IV acute graft-versus-host disease were 44% and 19%, respectively, with no cases of chronic graft-versus-host disease. The present study showed the safety of direct intrabone infusion of cord blood. Further analysis is required to confirm the efficacy of intrabone single cord blood transplantation with non-irradiated reduced-intensity conditioning for adult patients with hematological malignancy. This study was registered with UMIN-CTR, number 000000865.
  • Naohiro Miyashita, Tomoyuki Endo, Masahiro Onozawa, Daigo Hashimoto, Takeshi Kondo, Katsuya Fujimoto, Kaoru Kahata, Junichi Sugita, Hideki Goto, Toshihiro Matsukawa, Satoshi Hashino, Takanori Teshima
    TRANSPLANT INFECTIOUS DISEASE 19 3 2017年06月 [査読有り][通常論文]
     
    Background: Human herpesvirus 6 (HHV-6) encephalitis/myelitis is now a well-known complication after allogeneic stem cell transplantation (allo-HSCT), particularly after cord blood transplantation (CBT). In this study, we evaluated the risk factors of HHV-6 encephalitis/myelitis. Methods: We evaluated 253 patients who received allo-HSCT from 2007 to 2015 at our institute. HHV-6 encephalitis/myelitis was defined as HHV-6 DNA detection in the cerebrospinal fluid or peripheral blood by polymerase chain reaction in the presence of typical manifestations without other concurrent condition that led to the manifestations. Results: HHV-6 encephalitis/myelitis occurred in 11 patients (4.5%) (9 encephalitis, 3.7%; 2 myelitis, 0.8%). Multivariate analysis showed that CBT, mycophenolate mofetil (MMF) for graft-versus-host disease prophylaxis, history of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and engraftment syndrome (ES) were significantly associated with incidence of HHV-6 encephalitis/myelitis (P=.025, P=.017, P=.017, and P=.014, respectively). Conclusion: Although it has been shown that CBT, ES, and history of allo-HSCT are risk factors for HHV-6 encephalitis/myelitis, our study demonstrated MMF is also a risk factor for the disease.
  • M. Kanaya, Y. Hayashi, D. Hashimoto, T. Endo, J. Sugita, H. Ohigashi, J. Hashiguchi, T. Matsukawa, S. Matsuoka, M. Kosugi-Kanaya, H. Goto, M. Onozawa, K. Kahata, K. Fujimoto, T. Kondo, K. Akizawa, H. Shibuya, C. Shimizu, T. Teshima
    BONE MARROW TRANSPLANTATION 52 5 778 - 780 2017年05月 [査読有り][通常論文]
  • Toshihiro Matsukawa, Daigo Hashimoto, Junichi Sugita, Seitarou Nakazawa, Takae Matsushita, Haruhiko Kashiwazaki, Hideki Goto, Masahiro Onozawa, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Satoshi Hashino, Yutaka Yamazaki, Takanori Teshima
    INTERNATIONAL JOURNAL OF HEMATOLOGY 104 1 117 - 124 2016年07月 [査読有り][通常論文]
     
    Allogeneic hematopoietic stem cell transplantation is a curable treatment for hematological diseases. Graft-versus-host disease (GVHD) causes morbidity and mortality after HSCT. Methotrexate (MTX) is used for GVHD prophylaxis, but its appropriate dose remains unclear. In the present study, we compared the efficacy and toxicity of 15-10-10 MTX (day +1: 15 mg/m(2); days +3 and +6: 10 mg/m(2)) with 10-7-7 MTX (day +1: 10 mg/m(2); day +3 and +6: 7 mg/m(2)) in combination with tacrolimus. The cumulative incidence rates of grades II-IV acute GVHD, grades III-IV acute GVHD and chronic GVHD in the 15-10-10 MTX and 10-7-7 MTX groups did not differ to a statistically significant extent. The median time for neutrophil engraftment in the 15-10-10 MTX group was 16 days (range, 11-31 days), while that in the 10-7-7 group was 15 days (range, 12-19 days) (P = 0.024). Moreover, the median time for platelet recovery was significantly shorter in the 10-7-7 MTX group (22 days; range, 13-49 days) than that in the 15-10-10 MTX group (27 days; range, 9-405 days) (P = 0.027). The duration of oral mucositis was significantly shorter in the patients who received a reduced dose of MTX (median, 4.5 vs 13.0 days; P = 0.013). In conclusion, GVHD prophylaxis with a reduced dose of MTX was associated with earlier engraftment and earlier recovery from mucositis in comparison to a standard dose of MTX, without affecting the incidence of GVHD.
  • Souichi Shiratori, Katsuya Fujimoto, Machiko Nishimura, Kanako C. Hatanaka, Mizuha Kosugi-Kanaya, Kohei Okada, Junichi Sugita, Akio Shigematsu, Daigo Hashimoto, Tomoyuki Endo, Takeshi Kondo, Riichiro Abe, Satoshi Hashino, Yoshihiro Matsuno, Hiroshi Shimizu, Takanori Teshima
    HEMATOLOGICAL ONCOLOGY 34 1 9 - 16 2016年03月 [査読有り][通常論文]
     
    Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS. With a median follow-up period of 954days after HSCT, the estimated 3-year overall survival was 85.7% (95% confidence interval, 33.4-97.9%) with no non-relapse mortality. Five patients relapsed after RIC-HSCT; however, in four patients whose relapse was detected only from the skin, persistent complete response was achieved in one patient, and the disease was manageable in other three patients by the tapering of immunosuppressants and donor lymphocyte infusion, suggesting that graft-versus-lymphoma effect and down-staging' effect from advanced stage to early stage by HSCT improve the prognosis of advanced-stage MF/SS. These results suggest that RIC-HSCT is an effective treatment for advanced MF/SS. Copyright (c) 2014 John Wiley & Sons, Ltd.
  • 遠藤知之, 嶋村剛, 後藤了一, 藤本勝也
    血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 平成27年度 総括・分担研究報告書 9‐11  2016年 [査読無し][通常論文]
  • 嶋村剛, 遠藤知之, 後藤了一
    血液製剤によるHIV/HCV重複感染患者の肝移植に関する研究 平成27年度 総括・分担研究報告書 21‐22  2016年 [査読無し][通常論文]
  • Kasahara K, Onozawa M, Miyashita N, Yokohata E, Yoshida M, Kanaya M, Kosugi-Kanaya M, Takemura R, Takahashi S, Sugita J, Shigematsu A, Takahata M, Fujisawa S, Hashimoto D, Fujimoto K, Endo T, Kondo T, Teshima T
    Case reports in hematology 2016 2373902  2016年 [査読有り][通常論文]
  • Yuki Tazawa, Akio Shigematsu, Kumiko Kasashi, Junichi Sugita, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima, Ken Iseki, Mitsuru Sugawara, Yoh Takekuma
    Journal of pharmaceutical health care and sciences 2 18 - 18 2016年 [査読有り][通常論文]
     
    BACKGROUND: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation. We also carried out an in vivo study using rats to verify the dose adjustment. METHODS: This study included 20 adult patients. ETP was administered intravenously at a dose of 15 mg/kg once daily for 2 days (total dose: 30 mg/kg) combined with standard conditioning of cyclophosphamide and total body irradiation. In an in vivo study using rats, ETP was administered intravenously at a dose of 15 mg/kg or an adjusted dose. The ETP plasma concentration was determined by using HPLC. The pharmacokinetic parameters were estimated by using a 1-compartment model. RESULTS: The peak concentration (Cmax) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of Cmax, 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL). A significant relationship was found between Cmax and AUC (R = 0.85, P < 0.05). Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively). We predicted Vd of rats by body weight of rats (with normal albumin levels and renal function), and the dose of ETP was adjusted using predicted Vd. In the dose adjustment group, the target plasma ETP concentration was achieved and the variation of plasma ETP concentration was decreased. CONCLUSION: The results suggested that inter-individual variation of plasma concentration of ETP could be reduced by predicting Vd. Prediction of Vd is effective for reducing individual variation of ETP concentration and might enable a good therapeutic effect to be achieved.
  • Mutsumi Nishida, Akio Shigematsu, Megumi Sato, Yusuke Kudo, Satomi Omotehara, Tatsunori Horie, Takahito Iwai, Tomoyuki Endo, Akihiro Iguchi, Hitoshi Shibuya, Kanako Hatanaka, Chikara Shimizu, Takanori Teshima
    CLINICAL TRANSPLANTATION 29 8 697 - 704 2015年08月 [査読有り][通常論文]
     
    Gastrointestinal graft-versus-host disease (GI-GVHD) is a major and life-threatening complication of hematopoietic stem cell transplantation (HSCT). This study evaluated the efficacy of ultrasonography (US) for assessing and monitoring GI-GVHD. GI tract was evaluated by US in 81 patients. US findings were positive in 43 patients, including 11 false positive, and negative in 38 patients. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of US for the diagnosis of GI-GVHD were 100%, 78%, 74%, 100%, and 86%, respectively. Diffuse wall thickening of the ileum was the most frequent finding in patients with GI-GVHD. Severity of GI-GVHD was correlated with the thickness of internal low echoic layer of the wall, the echogenicity of mesenteric fat tissue, and the intensity of Doppler signaling. We classified US findings of GI-GVHD into four USgrades. There was a significant correlation between clinical stage of GI-GVHD and the US grade. These ultrasonographic abnormalities were improved with clinical improvement of GI-GVHD upon treatment. Thus, US is an effective and efficient non-invasive means of identifying the extent and severity of GI-GVHD and monitoring response to treatment.
  • Keisuke Imafuku, Yukiko Nomura, Chihiro Nakayama, Riichiro Abe, Tomoyuki Endo, Hiroshi Shimizu
    British journal of haematology 170 2 140 - 140 2015年07月 [査読有り][通常論文]
  • Leonard Christopher Schmeel, Frederic Carsten Schmeel, Young Kim, Sabine Blaum-Feder, Tomoyuki Endo, Ingo G. H. Schmidt-Wolf
    ANTICANCER RESEARCH 35 3 1369 - 1376 2015年03月 [査読有り][通常論文]
     
    Background/Aim: Novel agents such as lenalidomide and bortezomib have significantly improved today's therapy of multiple myeloma. Despite recent innovations, new therapeutic options are needed. The Wingless-related integration site (WNT) pathway is aberrantly activated in lymphoma and myeloma and therefore renders WNT signaling molecules attractive for the development of targeted therapies. Flunarizine was used in this study as it has chemical features similar to those of other known WNT inhibitors and already proven proapoptotic properties in leukemia cells. Materials and Methods: The antitumor apoptotic effect of flunarizine at doses ranging from 0.1-200 mu M was investigated on three human lymphoma cell lines, one in urine and four human myeloma cell lines by 3'3-Dihexyloxacarbocyanine iodide and propidium iodide staining in flow cytometry. Results: Flunarizine induced significant apoptotic activity in all tested myeloma and lymphoma cell lines in a dose-dependent manner. Conclusion: Our results reveal a significant selective induction of apoptosis by flunarizine and suggest an in vivo effect against lymphoma and myeloma.
  • Leonard Christopher Schmeel, Frederic Carsten Schmeel, Young Kim, Sabine Blaum-Feder, Tomoyuki Endo, Ingo G. H. Schmidt-Wolf
    ANTICANCER RESEARCH 35 2 835 - 841 2015年02月 [査読有り][通常論文]
     
    Background/Aim: Multiple myeloma, a well-known but still incurable disease, is a hematological malignancy of B-lymphocytes. While standard chemotherapy regimens have been used for years, novel agents, such as lenalidomide and bortezomib, have become an essential part of today's therapies. Nevertheless, new therapeutical strategies are required in the future. Aberrant activation of wingless-related integration site (WNT)/beta-catenin signaling promotes the development of several types of cancer. Recently, it has been demonstrated that the WNT pathway is also activated in lymphoma and myeloma. Thus, the WNT signaling molecules are attractive candidates for the development of targeted therapies. To this extent, we recently confirmed that the diuretic agent ethacrynic acid (EA) and the antifungal agent ciclopirox olamine (CIC) inhibit WNT signaling. Cinnarizine has similar chemical features to those of CIC. Materials and Methods: Thus, in this study the antitumor effect of cinnarizine on myeloma and lymphoma cells was investigated by DiOC6 and propidium iodide (PI)-staining in flow cytometry. Results: Cinnarizine triggered a significant apoptotic activity in all tested myeloma and lymphoma cell lines in a concentration-dependent manner. Interestingly, healthy cells were mainly unaffected. Conclusion: These results reveal a significant selective induction of apoptosis by cinnarizine that might result from an inhibition of WNT signaling and suggest an in vivo efficacy against lymphoma and myeloma.
  • Souichi Shiratori, Mizuha Kosugi-Kanaya, Akio Shigematsu, Hajime Kobayashi, Satoshi Yamamoto, Naoki Kobayashi, Hiroshi Iwasaki, Akio Mori, Yasuyuki Kunieda, Yutaka Tsutsumi, Mitsutoshi Kurosawa, Yasutaka Kakinoki, Tomoyuki Endo, Takeshi Kondo, Satoshi Hashino, Takanori Teshima
    LEUKEMIA & LYMPHOMA 56 9 2592 - 2597 2015年 [査読有り][通常論文]
     
    Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of non-Hodgkin lymphoma and displays an aggressive clinical course with poor outcome. To identify prognostic factors for AITL, we retrospectively analyzed 36 patients with AITL. The median age was 74 years with 83% of the patients having advanced stage. Eighty-three percent received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like chemotherapies, resulting in an overall response rate of 63%. With a median follow-up of 9 years, the estimated overall survival at 5 years was 33.3%. Median serum level of soluble interleukin-2 receptor (sIL-2R) was 5615 U/mL at diagnosis, and over 10 000 U/mL of sIL-2R was identified as a significant poor prognostic factor, independent of the International Prognostic Index, Prognostic Index for peripheral T-cell lymphoma and Prognostic index for AITL (hazard ratio [HR], 4.42; 95% confidence interval [ CI], 1.49-13.11; log-rank, p < 0.01). Our study shows that an ultra-high level of serum sIL-2R at diagnosis is a significant poor prognostic biomarker for AITL.
  • Ishio T, Endo T, Okada K, Shigematsu A, Hashino S, Teshima T
    Case reports in hematology 2015 949265  2015年 [査読有り][通常論文]
  • Toshinari Miyauchi, Riichiro Abe, Yusuke Morita, Maki Adachi, Keiko Shiba, Yohei Hamade, Nan Saito, Machiko Nishimura, Makoto Ibata, Kohei Okada, Akio Shigematsu, Tomoyuki Endo, Kazuhiro Kawai, Takanori Teshima, Hiroshi Shimizu
    ACTA DERMATO-VENEREOLOGICA 95 8 1024 - 1025 2015年 [査読有り][通常論文]
  • Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T
    Transpl Infect Dis 16 5 797 - 801 2014年10月 [査読有り][通常論文]
  • Souichi Shiratori, Kentaro Wakasa, Kohei Okada, Junichi Sugita, Koji Akizawa, Akio Shigematsu, Daigo Hashimoto, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Chikara Shimizu, Satoshi Hashino, Takanori Teshima
    CLINICAL TRANSPLANTATION 28 6 656 - 661 2014年06月 [査読有り][通常論文]
     
    To examine risk factors for Stenotrophomonas maltophilia (S.maltophilia) infection during allogeneic hematopoietic stem cell transplantation (allo-HSCT), we retrospectively analyzed 259 patients who underwent allo-HSCT. Not only S.maltophilia infection but also S.maltophilia colonization was associated with mortality during allo-HSCT. Among 52 episodes in 39 patients in whom S.maltophilia was detected, documented infection developed in 33 episodes (25 patients). The onset of S.maltophilia infection in the period from the conditioning regimen to engraftment was associated with a high mortality rate. Breakthrough S.maltophilia infection developed in 24% of the patients during prophylactic administration of fluoroquinolones, to which S.maltophilia is sensitive. Reinsertion of a central venous catheter (CVC) immediately after removal was suggested to be a risk for persistent S.maltophilia infection in the period of neutropenia. Our results indicated that (i) onset of S.maltophilia infection in the period from the conditioning therapy to engraftment and (ii) removal and immediate reinsertion of a CVC as treatment after the onset of S.maltophilia infection are possible risk factors for S.maltophilia-related mortality during allo-HSCT.
  • Yusuke Shono, Souichi Shiratori, Mizuha Kosugi-Kanaya, Satoshi Ueha, Junichi Sugita, Akio Shigematsu, Takeshi Kondo, Daigo Hashimoto, Katsuya Fujimoto, Tomoyuki Endo, Mitsufumi Nishio, Satoshi Hashino, Yoshihiro Matsuno, Kouji Matsushima, Junji Tanaka, Masahiro Imamura, Takanori Teshima
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 20 4 495 - 500 2014年04月 [査読有り][通常論文]
     
    Idiopathic cytopenias are frequently observed in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We have previously reported the effect of graft-versus-host disease (GVHD) on bone marrow (BM) in murine models, indicating that the osteoblast injury mediated by donor T cells was associated with bone marrow suppression and delayed immune reconstitution. In this study, we prospectively evaluated the relevance of these findings in 51 patients. Patients with chronic GVHD manifested the loss of osteoblasts, contributing to cytopenic symptoms (P =.0427 compared with patients without cytopenic symptoms). The loss of osteoblasts was significantly associated with the extensive type of chronic GVHD (P =.012), and flow cytometric analyses revealed lower numbers of CD19(+) B cells and a significantly increased CD4 to CD8 ratio (P.0002) in these patients. Our data, for the first time to our knowledge, summarize the detailed analyses of the effect of GVHD on BM in the clinical allo-HSCT patients. (c) 2014 American Society for Blood and Marrow Transplantation.
  • Leonard Christopher Schmeel, Frederic Carsten Schmeel, Young Kim, Tomoyuki Endo, Desheng Lu, Ingo G. H. Schmidt-Wolf
    Anticancer Research 33 11 4719 - 4726 2013年11月 [査読有り][通常論文]
     
    Background/Aim: Recent investigations have shown that the Wnt signaling pathway is constitutively activated in multiple myeloma (MM), thereby promoting an exaggerated cell proliferation. Thus, influencing the Wnt pathway might represent a promising target in myeloma treatment. Materials and Methods: The present study investigated whether a combination of ethacrynic acid (EA) and ciclopirox olamine (CIC) with piceatannol (PIC) would influence the Wnt pathway and viability of human and murine myeloma cell lines by using DiOC6 and propidium iodide (PI) staining, flow cytometry and immunoblotting. Results: The combination of EA with PIC as well as the combination of CIC with PIC had a significant additive effect on the vitality of myeloma cells compared to singleagent application, while healthy cells remained mainly unaffected. Additionally, EA and CIC altered the expression of β-catenin itself and its downstream factors. Conclusion: A combination of Wnt inhibitors could lead to novel treatment options for MM patients.
  • Takeshi Nishijima, Misao Takano, Michiyo Ishisaka, Hirokazu Komatsu, Hiroyuki Gatanaga, Yoshimi Kikuchi, Tomoyuki Endo, Masahide Horiba, Satoru Kaneda, Hideki Uchiumi, Tomohiko Koibuchi, Toshio Naito, Masaki Yoshida, Natsuo Tachikawa, Mikio Ueda, Yoshiyuki Yokomaku, Teruhisa Fujii, Satoshi Higasa, Kiyonori Takada, Masahiro Yamamoto, Shuzo Matsushita, Masao Tateyama, Yoshinari Tanabe, Hiroaki Mitsuya, Shinichi Oka
    Internal Medicine 52 7 735 - 744 2013年 [査読有り][通常論文]
     
    Objective To compare the efficacy and safety of fixed-dose abacavir/lamivudine (ABC/3TC) and tenofovir/ emtricitabine (TDF/FTC) with ritonavir-boosted atazanavir (ATV/r) in treatment-naïve Japanese patients with HIV-1 infection. Methods A 96-week multicenter, randomized, open-label, parallel group pilot study was conducted. The endpoints were times to virologic failure, safety event and regimen modification. Results 109 patients were enrolled and randomly allocated (54 patients received ABC/3TC and 55 patients received TDF/FTC). All randomized subjects were analyzed. The time to virologic failure was not significantly different between the two arms by 96 weeks (HR, 2.09 95% CI, 0.72-6.13 p=0.178). Both regimens showed favorable viral efficacy, as in the intention-to-treat population, 72.2% (ABC/3TC) and 78.2% (TDF/ FTC) of the patients had an HIV-1 viral load < 50 copies/mL at 96 weeks. The time to the first grade 3 or 4 adverse event and the time to the first regimen modification were not significantly different between the two arms (adverse event: HR 0.66 95% CI, 0.25-1.75, p=0.407) (regimen modification: HR 1.03 95% CI, 0.33- 3.19, p=0.964). Both regimens were also well-tolerated, as only 11.1% (ABC/3TC) and 10.9% (TDF/FTC) of the patients discontinued the allocated regimen by 96 weeks. Clinically suspected abacavir-associated hypersensitivity reactions occurred in only one (1.9%) patient in the ABC/3TC arm. Conclusion Although insufficiently powered to show non-inferiority of viral efficacy of ABC/3TC relative to TDF/FTC, this pilot trial suggested that ABC/3TC with ATV/r is a safe and efficacious initial regimen for HLA-B*5701-negative patients, such as the Japanese population. © 2013 The Japanese Society of Internal Medicine.
  • Takeshi Nishijima, Hiroyuki Gatanaga, Takuro Shimbo, Hirokazu Komatsu, Tomoyuki Endo, Masahide Horiba, Michiko Koga, Toshio Naito, Ichiro Itoda, Masanori Tei, Teruhisa Fujii, Kiyonori Takada, Masahiro Yamamoto, Toshikazu Miyakawa, Yoshinari Tanabe, Hiroaki Mitsuya, Shinichi Oka
    PloS one 8 8 e73639  2013年 [査読有り][通常論文]
     
    BACKGROUND: Whether tenofovir nephrotoxicity is reversible after its withdrawal is unknown. Furthermore, there are no data on the viral efficacy of raltegravir (RAL) plus ritonavir-boosted Darunavir (DRV/r) in patients with suppressed viral load. METHODS: This multicenter, randomized trial compared renal function and viral efficacy in patients with suppressed viral load treated with RAL+DRV/r and ritonavir-boosted lopinavir (LPV/r) plus tenofovir/emtricitabine (TVD), who had been previously on LPV/r+TVD. The primary endpoint was the proportion of patients with >10% improvement in estimated glomerular filtration rate (eGFR) at 48 weeks calculated with Cockcroft-Gault equation. RESULTS: 58 randomized and treatment-exposed patients were analyzed (28 on RAL+DRV/r and 30 on LPV/r+TVD). Greater than 10% improvement in eGFR was noted in 6 (25%) out of 24 with RAL+DRV/r and 3 (11%) of 28 with LPV/r+TVD, and the difference was not statistically significant (p=0.272, 95% CI -0.067 to 0.354). Sensitivity analyses using three other equations for eGFR showed the same results. Urinary β2 microglobulin, a sensitive marker of tenofovir tubulopathy, significantly improved with RAL+DRV/r than with LPV/r+TVD (-271 versus -64 µg/gCr, p=0.026). Per protocol analysis showed that the HIV-RNA was <50 copies/mL at week 48 in all patients of both arms (24 in RAL+DRV and 29 in LPV/r+TVD). CONCLUSIONS: Switching LPV/r+TVD to RAL+DRV/r did not significantly increase the proportion of patients who showed >10% improvement in renal function among those with relatively preserved eGFR. However, the switch improved urinary β2 microglobulin, suggesting that discontinuation of TDF might be beneficial in the long-term. RAL+DRV/r showed favorable viral efficacy in patients with suppressed viral load. TRIAL REGISTRATION: ClinicalTrials.gov NCT01294761 http://clinicaltrials.gov/ct2/show/NCT01294761?term=SPARE&rank=2, Umin Clinical Trials Registry UMIN000005116 http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000006083&language=J).
  • Takahata M, Hashino S, Fujimoto K, Endo T, Kobayashi N, Kurosawa M, Iwasaki H, Miyake T, Kohda K, Maekawa I, Sasagawa H, Tsustumi Y, Miyagishima T, Tanaka J, Imamura M, Teshima T
    [Rinsho ketsueki] The Japanese journal of clinical hematology 53 12 1983 - 1990 2012年12月 [査読有り][通常論文]
  • Haruhiko Kashiwazaki, Takae Matsushita, Junichi Sugita, Akio Shigematsu, Kumiko Kasashi, Yutaka Yamazaki, Takashi Kanehira, Takeshi Kondo, Tomoyuki Endo, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Masahiro Imamura, Yoshimasa Kitagawa, Nobuo Inoue
    SUPPORTIVE CARE IN CANCER 20 5 933 - 939 2012年05月 [査読有り][通常論文]
     
    Severe oral mucositis developed in allogeneic hematopoietic stem cell transplantation (HSCT) accompanies intolerable pain and risk for systemic bacteremia infection. Conventional stem cell transplantation (CST) and reduced-intensity regimens for allogeneic HSCT (RIST) may differently affect the occurrence and severity of oral mucositis. Here, we comparatively examined oral mucositis in patients undergoing CST and that in RIST patients to search for measures to alleviate oral mucositis. We retrospectively analyzed the data of 130 consecutive patients undergoing HSCT (conventional, 60; RIST, 70). Oral mucositis was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. We also investigated the risk factors for severe oral mucositis in each regimen. The incidence of oral mucositis was not significantly different between RIST and CST patients. The use of opioid analgesics to control pain due to oral mucositis was significantly less in patients undergoing RIST compared with those receiving CST. The risk factors for severe oral mucositis, determined by univariate and multivariate analyses, were "younger age (<40)" in CST and "longer duration of neutropenia (>= 14 days)" in RIST. Although the incidences of oral mucositis were almost the same, the need for opioid analgesics and the risk factors for severe oral mucositis differed between CST and RIST patients.
  • Young Kim, Sanna-Marie Gast, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
    LEUKEMIA RESEARCH 36 5 598 - 600 2012年05月 [査読有り][通常論文]
     
    It was recently confirmed that the diuretic agent ethacrynic acid (EA) inhibits Wnt/beta catenin signaling in myeloma. This study investigated the antitumor effect of EA in vivo in a murine myeloma model. In vivo, tumor growth was significantly reduced and overall survival significantly prolonged in mice treated with EA as compared to untreated mice. Interestingly, this effect was higher as compared to the effect by lenalidomide, a commonly used drug against myeloma. These results reveal a significant in vivo effect by EA against myeloma. (C) 2012 Elsevier Ltd. All rights reserved.
  • Haruhiko Kashiwazaki, Takae Matsushita, Junichi Sugita, Akio Shigematsu, Kumiko Kasashi, Yutaka Yamazaki, Takashi Kanehira, Satoshi Yamamoto, Takeshi Kondo, Tomoyuki Endo, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Masahiro Imamura, Yoshimasa Kitagawa, Nobuo Inoue
    SUPPORTIVE CARE IN CANCER 20 2 367 - 373 2012年02月 [査読有り][通常論文]
     
    Little is known about the effects of professional oral health care (POHC) on the outcome of hematopoietic stem cell transplantation (HSCT). We evaluated the effects of POHC given by dentists and dental hygienists on the development of oral mucositis and febrile neutropenia (FN) after allogeneic bone marrow transplantation (BMT).We retrospectively studied 140 adult patients who had received allogeneic BMT, with or without POHC, in our hospital consecutively between February 2002 and December 2009. Oral mucositis was evaluated according to the World Health Organization scale.The incidence of oral mucositis was 66.7% (52/78) in the patients who had received POHC, compared to 93.5% (58/62) in the non-POHC group (P < 0.001). The incidence of FN and the maximal level of CRP were also significantly lower in the POHC group. Multivariate analysis revealed that the POHC was significantly associated with the incidence of oral mucositis (odds ratio, 7.58; 95%CI, 2.45-23.34; P < 0.001).We concluded that POHC reduced the incidences of oral mucositis and FN by upgrading the overall oral hygiene during HSCT.
  • Toshihiro Matsukawa, Hideki Goto, Kenta Takahashi, Shinsuke Asanuma, Atsushi Yasumoto, Mutsumi Takahata, Akio Shigematsu, Tomoyuki Endo, Junji Tanaka, Satoshi Hashino, Shinya Tanaka, Masahiro Imamura
    INTERNATIONAL JOURNAL OF HEMATOLOGY 95 2 217 - 222 2012年02月 [査読有り][通常論文]
     
    Cytomegalovirus (CMV) infection is latent in the majority of adult humans. The reactivation of CMV causes pneumonia and gastrointestinal disease in severely immunosuppressed patients, who consequently suffer very high mortality due to CMV central nervous system disease. We report here a case involving a 28-year-old female patient with mycosis fungoides who underwent umbilical cord blood transplantation three times and developed CMV ventriculoencephalitis. The patient's CMV viremia was successfully preempted with ganciclovir (GCV) as indicated by undetectable CMV antigenemia; despite this successful treatment, the patient developed CMV ventriculoencephalitis. Foscarnet (FCV) therapy led to a temporary recovery, after which CMV ventriculoencephalitis recurred, and the patient died after receiving combination GCV and FCV therapy. Autopsy samples revealed CMV ventriculoencephalitis, as indicated by numerous inclusion-bearing cells (Owl's eye). It is likely that this patient harbored a GCV-resistant CMV strain; however, it was not possible to obtain nucleic acids suitable for use in assessing this possibility.
  • Young Kim, Matthias Schmidt, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
    IN VIVO 25 6 887 - 893 2011年11月 [査読有り][通常論文]
     
    Background: Aberrant activation of Wnt/beta-catenin signaling promotes the development of several types of cancer. Recently, it has been demonstrated that Wilt pathway is also activated in myeloma. Therefore, the Wnt/beta-catenin signaling molecules are attractive candidates for development of targeted therapies for this disease. Materials and Methods: This study investigated the antitumor effect of ciclopirox olamine (CIC) in vitro and in vivo in a murine myeloma model. Results: CIC demonstrated major apoptotic activity in different human and murine myeloma and lymphoma cell lines, as well as in human primary cells. In addition, beta-catenin expression was down-regulated when CIC was added to lymphoma cells. Interestingly, in vitro, a significant additive effect was seen with the combination of lenalidomide plus CIC as compared to single applications. In vivo, tumor growth, was significantly reduced and overall survival increased in mice treated with CIC as compared to untreated mice. Conclusion: These results reveal a significant selective induction of apoptosis by CIC and suggest a significant in vivo effect against myeloma.
  • Ikumi Kasahara, Mitsufumi Nishio, Tomoyuki Endo, Katsuya Fujimoto, Takao Koike, Naomi Sugimori, Takamasa Katagiri, Shinji Nakao
    LEUKEMIA RESEARCH 35 9 E147 - E148 2011年09月 [査読有り][通常論文]
  • Young Kim, Petra Alpmann, Sabine Blaum-Feder, Simon Kraemer, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
    LEUKEMIA RESEARCH 35 8 1070 - 1073 2011年08月 [査読有り][通常論文]
     
    We recently confirmed that ciclopirox olamine inhibits Wnt/beta catenin signalling in myeloma. Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine. In this study the anti-tumor effect of GF was investigated. GF demonstrated a major apoptotic activity in various human and murine myeloma and lymphoma cell lines as well as in human primary cells. In vivo, tumor growth as well as overall survival were significantly reduced in mice treated with GF as compared to untreated mice. In conclusion, our results reveal a significant selective induction of apoptosis by GF and suggest a significant in vivo effect against myeloma. (C) 2010 Elsevier Ltd. All rights reserved.
  • Matthias Schmidt, Young Kim, Sanna-Marie Gast, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
    IN VIVO 25 3 325 - 333 2011年05月 [査読有り][通常論文]
     
    Background: It was recently confirmed that ethacrynic acid (EA) inhibits Wnt/beta catenin signalling in myeloma. Materials and Methods: This study investigated the antitumor effect of EA in vitro and in vivo in a murine myeloma model. Results: EA demonstrated major apoptotic activity in different human and murine myeloma and lymphoma cell lines, as well as in human primary cells. In addition beta-catenin expression was down-regulated when EA was added to lymphoma cells. In vivo, tumor growth, as well as overall survival, was significantly reduced in mice treated with EA as compared to untreated mice. Interestingly, in vitro, a significant additive effect was seen with the combination of lenalidomide plus EA as compared to single applications. Conclusion: These results reveal a significant selective induction of apoptosis by EA and suggest a significant in vivo effect against myeloma.
  • Masahiro Onozawa, Kazumasa Ohmura, Makoto Ibata, Junko Iwasaki, Kohei Okada, Ikumi Kasahara, Keisuke Yamaguchi, Kanako Kubota, Shinichi Fujisawa, Akio Shigematsu, Tomoyuki Endo, Takeshi Kondo, Satoshi Hashino, Junji Tanaka, Yoshihiro Matsuno, Masahiro Asaka, Masahiro Imamura
    EUROPEAN JOURNAL OF HAEMATOLOGY 86 4 347 - 349 2011年04月 [査読有り][通常論文]
  • Kanda M, Shigematsu A, Okada K, Kasahara I, Iwasaki J, Yamaguchi K, Onozawa M, Endo T, Akizawa K, Ishiguro N, Hashino S, Imamura M
    [Rinsho ketsueki] The Japanese journal of clinical hematology 52 3 118 - 123 3 2011年03月 [査読有り][通常論文]
  • Young Kim, Guido Reifenberger, Desheng Lu, Tomoyuki Endo, Dennis A. Carson, Sanna-Marie Gast, Karoline Meschenmoser, Michael Nowak, Ingo G. H. Schmidt-Wolf
    ANTICANCER RESEARCH 31 2 725 - 730 2011年02月 [査読有り][通常論文]
     
    Recent studies have implicated genetic and epigenetic aberrations resulting in aberrant activation of the Wingless-Int (Wnt) pathway and thus influencing the initiation and progression of multiple myeloma (MM). Of major importance, these findings may lead to novel treatment strategies exploiting targeted modulation of Wnt signaling. This review describes the current status of knowledge concerning the role of Wnt pathway alteration in MM and outlines future lines of research and their clinical perspectives.
  • Young Kim, Petra Alpmann, Sabine Blaum-Feder, Simon Kraemer, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
    IN VIVO 25 1 99 - 103 2011年01月 [査読有り][通常論文]
     
    Background: It was recently confirmed that the antifungal agent ciclopirox olamine inhibits Wnt/beta catenin signaling in myeloma. Piroctone olamine (PO) has very similar chemical features to ciclopirox olamine. Materials and Methods: This study investigated the antitumor effect of PO in vitro and in vivo in a murine myeloma model. Results: PO demonstrated a major apoptotic activity in various human and murine myeloma and lymphoma cell lines, as well as in human primary cells. In vivo, tumor growth, as well as overall survival, was significantly reduced in mice treated with PO as compared to untreated mice. Interestingly, concerning tumor growth and survival of the animals, a significant additive effect was seen by the combination of lenalidomide plus PO as compared to single application. Conclusion: These results reveal a significant selective induction of apoptosis by PO and suggest a significant in vivo effect against myeloma.
  • Shigematsu A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Yamaguchi K, Wakasa K, Takahata M, Goto H, Ito S, Takemura R, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M
    Transplant infectious disease : an official journal of the Transplantation Society 12 5 412 - 420 2010年10月 [査読有り][通常論文]
  • Mutsumi Takahata, Satoshi Hashino, Kohei Okada, Masahiro Onozawa, Kaoru Kahata, Junichi Sugita, Akio Shigematsu, Takeshi Kondo, Satoshi Yamamoto, Tomoyuki Endo, Mitsufumi Nishio, Yoichi M. Ito, Junji Tanaka, Takao Koike, Masahiro Asaka, Masahiro Imamura
    AMERICAN JOURNAL OF HEMATOLOGY 85 4 243 - 248 2010年04月 [査読有り][通常論文]
     
    Reduced intensity conditioning (RIC) regimens are widely used in allogeneic stem cell transplantation (SCT). In this study, we retrospectively investigated the clinical outcomes of RIC with fludarabine (Flu; 180 mg/m(2)), intravenous busulfan (BU; 6.4 mg/kg) or oral BU (8 mg/kg), and low-dose total body irradiation (TBI; 4 Gy) (Flu-BU2-TBI) in 66 patients (median age: 54.5 years) with various hematological malignancies. Thirty-eight patients (58%) were high-risk patients (median age: 56 years). The overall survival rate at 2 years of the high-risk patients was 64.5%, which was comparable to the survival rate of 70.9% in standard-risk patients (P = 0.68). The relapse rates at 2 years in the standard-risk and high-risk patients were 16 and 28%, respectively, and day 100 treatment-related mortality rates were 0 and 6%, respectively. The Flu-BU2-TBI regimen for high-risk patients showed therapeutic effects equivalent to those for standard-risk patients and favorable outcomes compared with those of other previous RIC regimens. Am. J. Hematol. 84:243-248, 2010. (C) 2010 Wiley-Liss, Inc.
  • Lei Wang, Hiroshi Nishihara, Taichi Kimura, Yasutaka Kato, Mishie Tanino, Mitsufumi Nishio, Masato Obara, Tomoyuki Endo, Takao Koike, Shinya Tanaka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 395 1 111 - 115 2010年04月 [査読有り][通常論文]
     
    DOCK2; a member of the CDM protein family, regulates cell motility and cytokine production through the activation of Rac in mammalian hematopoietic cells and plays a pivotal role in the modulation of the immune system. Here we demonstrated the alternative function of DOCK2 in hematopoietic tumor cells, especially in terms of its association with the tumor progression. Immunostaining for DOCK2 in 20 cases of human B cell lymphoma tissue specimens including diffuse large B cell lymphoma and follicular lymphoma revealed the prominent expression of DOCK2 in all of the lymphoma cells. DOCK2-knockdown (KD) of the B cell lymphoma cell lines, Ramos and Raji, using the lentiviral shRNA system presented decreased cell proliferation compared to the control cells. Furthermore, the tumor formation of DOCK2-KD Ramos cell in nude mice was significantly abrogated. Western blotting analysis and pull-down assay using GST-PAK-RBD kimeric protein suggested the presence of DOCK2-Rac-ERK pathway regulating the cell proliferation of these lymphoma cells. This is the first report to clarify the prominent role of DOCK2 in hematopoietic malignancy. (C) 2010 Elsevier Inc. All rights reserved.
  • Takeshi Kondo, Atsushi Yasumoto, Kotaro Arita, Jun-ichi Sugita, Akio Shigematsu, Kohei Okada, Mutsumi Takahata, Masahiro Onozawa, Kaoru Kahata, Yukari Takeda, Masato Obara, Satoshi Yamamoto, Tomoyuki Endo, Mitsufumi Nishio, Norihiro Sato, Junji Tanaka, Satoshi Hashino, Takao Koike, Masahiro Asaka, Masahiro Imamura
    INTERNATIONAL JOURNAL OF HEMATOLOGY 91 2 310 - 321 2010年03月 [査読有り][通常論文]
     
    Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy. If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option. Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks. The outcome of allo-HSCT for AML patients with favorable cytogenetics seemed to be superior to that for AML patients with intermediate cytogenetics. In AML patients with favorable cytogenetics, the 3-year overall survival (OS) and relapse-free survival (RFS) rates were 88 and 76%, respectively, in the RIST group. Both the 3-year OS and RFS rates were 81% in the conventional stem cell transplantation (CST) group. The outcome of RIST for AML patients with favorable cytogenetics was comparable to that for patients who received CST despite the more advanced age and greater organ dysfunction in RIST group than in CST group. None of the patients died within 90 days after RIST. Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST. Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.
  • Katsuya Fujimoto, Tomoyuki Endo, Mitsufumi Nishio, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Ikumi Kasahara, Norihiro Sato, Takao Koike
    INTERNATIONAL JOURNAL OF HEMATOLOGY 90 5 601 - 604 2009年12月 [査読有り][通常論文]
     
    A 44-year-old female presented with asymptomatic leukocytosis and moderate splenomegaly. The diagnosis of splenic marginal zone lymphoma (SMZL) was made by a splenectomy. A virological examination revealed the patient to be a hepatitis B virus (HBV) carrier. The lymphocyte count in her peripheral blood decreased after splenectomy, but remained high for 2 years and bone marrow infiltration was obvious. Two years after the splenectomy, she was admitted for an acute flare-up of hepatitis B. The liver dysfunction improved without any medication and thereafter returned to the normal range within a few weeks. At the same time, the lymphocyte count in her peripheral blood rapidly decreased to normal levels. Atypical lymphocytes disappeared from the peripheral blood and bone marrow aspirates and biopsy specimen revealed complete remission of SMZL, including the disappearance of the clonal rearrangement of IgH-JH. There has been no recurrence of acute hepatitis and she has been in complete remission for SMZL for more than 6 years. The clinical course of this patient suggests that an immune response against HBV also affects the clearance of lymphoma cells. This is the first report that a complete remission was achieved in a patient with SMZL after a hepatitis B flare-up.
  • Desheng Lu, Jerry X. Liu, Tomoyuki Endo, Haowen Zhou, Shiyin Yao, Karl Willert, Ingo G. H. Schmidt-Wolf, Thomas J. Kipps, Dennis A. Carson
    PLOS ONE 4 12 e8294  2009年12月 [査読有り][通常論文]
     
    Background: Aberrant activation of Wnt/beta-catenin signaling promotes the development of several cancers. It has been demonstrated that the Wnt signaling pathway is activated in chronic lymphocytic leukemia (CLL) cells, and that uncontrolled Wnt/beta-catenin signaling may contribute to the defect in apoptosis that characterizes this malignancy. Thus, the Wnt signaling pathway is an attractive candidate for developing targeted therapies for CLL. Methodology/Principal Findings: The diuretic agent ethacrynic acid (EA) was identified as a Wnt inhibitor using a cell-based Wnt reporter assay. In vitro assays further confirmed the inhibitory effect of EA on Wnt/beta-catenin signaling. Cell viability assays showed that EA selectively induced cell death in primary CLL cells. Exposure of CLL cells to EA decreased the expression of Wnt/beta-catenin target genes, including LEF-1, cyclin D1 and fibronectin. Immune co-precipitation experiments demonstrated that EA could directly bind to LEF-1 protein and destabilize the LEF-1/beta-catenin complex. N-acetyl-L-cysteine (NAC), which can react with the a, beta-unsaturated ketone in EA, but not other anti-oxidants, prevented the drug's inhibition of Wnt/beta-catenin activation and its ability to induce apoptosis in CLL cells. Conclusions/Significance: Our studies indicate that EA selectively suppresses CLL survival due to inhibition of Wnt/beta-catenin signaling. Antagonizing Wnt signaling in CLL with EA or related drugs may represent an effective treatment of this disease.
  • Ikumi Kasahara, Mitsufumi Nishio, Satoshi Yamamoto, Tomoyuki Endo, Katsuya Fujimoto, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Norihiro Sato, Takao Koike
    INTERNATIONAL JOURNAL OF HEMATOLOGY 90 3 413 - 415 2009年10月 [査読有り][通常論文]
     
    Two multiple myeloma patients relapsed after autologous stem cell transplantation (ASCT). Conventional chemotherapy, including thalidomide, showed very little effect, but both patients responded well to a standard dose of bortezomib. One patient was treated with two additional cycles of bortezomib, but his clinical course suddenly deteriorated. Unrelated cord blood transplantation (CBT) with reduced-intensity conditioning regimen (RIC) was performed in refractory disease. After CBT, the clinical course was aggravated by tumor lysis syndrome and other conditions, thus resulting in patient death on day 34. Thereafter, we administered CBT with RIC on the second patient after just one course of bortezomib therapy since she was in partial remission. The second patient developed acute and chronic GVHD, and both responded to the steroid therapy. She has been in complete remission for more than 48 months after CBT. These results suggested that the timing of CBT with RIC may be very important, and cytoreduction with not only ASCT but also bortezomib could give a promising chance for a successful CBT.
  • Tomoyuki Endo, Katsuya Fujimoto, Mitsufumi Nishio, Satoshi Yamamoto, Masato Obara, Norihiro Sato, Takao Koike
    JOURNAL OF MEDICAL VIROLOGY 81 6 979 - 982 2009年06月 [査読有り][通常論文]
     
    The effect of highly active antiretroviral therapy (HAART) on hepatitis C virus (HCV) infection remains uncertain. This report describes the case of a man with hemophilia with HIV-HCV coinfection with persistent disappearance of HCV RNA after changing the HAART regimen. He had been treated with zidovudine, lamivudine, and indinavir for initial HAART and the HIV RNA level had been undetectable for more than 8 years. He had Suffered from chronic active hepatitis. The HAART regimen was changed to emtricitabine/tenofovir, atazanavir, and ritonavir because the patient preferred a once daily regimen. The HCV RNA level fell immediately and thereafter became undetectable by quantitative and qualitative assay at 5 and 7 months after the change of the HAART regimen, respectively. In contrast to other reported cases, he experienced neither increase of CD4+ T cells Count nor ALT flare-ups before HCV RNA clearance. The HCV RNA disappearance in this case may be due to the direct effect of HAART against HCV rather than restoration of cellular immunity to HCV. J. Med. Virol. 81:979-982, 2009. (c) 2009 Wiley-Liss Inc.
  • Akio Shigematsu, Atsushi Yasumoto, Satoshi Yamamoto, Junichi Sugita, Takeshi Kondo, Masahiro Onozawa, Kaoru Kahata, Tomoyuki Endo, Shuichi Ota, Norihiro Sato, Mutsumi Takahata, Kohei Okada, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Takao Koike, Masahiro Asaka, Masahiro Imamura
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 15 6 679 - 685 2009年06月 [査読有り][通常論文]
     
    Cytomegalovirus (CMV) infection is I of the major causes of morbidity in patients undergoing allogeneic stem cell transplantation (allo-SCT). The incidences of CMV antigenemia and CMV disease in 43 patients who received allogeneic bone marrow trans plantation (BMT) using a reduced-intensity conditioning (RIC) regimen, which mainly consisted of fluclarabine (Flu), busulfan (Bu), and total body irradiation (TBI), were compared with those in 68 patients who received a myeloablative conditioning (MAC) regimen, and risk factors for CMV antigenemia and CMV disease were identified. Before engraftment, grade 3-4 mucosal injury because of the conditioning regimen was significantly decreased in RIC patients (stomatitis: P=.02; diarrhea: P<.01). Rate of engraftment, incidences of acute graft-versus-host disease (aGVHD), and rate of corticosteroid administration were not different in RIC patients and MAC patients. Although the incidences of CMV antigenemia were not significantly different in RIC patients and MAC patients (64.1% versus 57.8%, log rank, P=.59), the incidence of CMV disease was significantly decreased in RIC patients (5.4% versus 20.3%, log rank, P=.04). CMV seropositivity in the patients (P<.01) and corticosteroid administration (P<.01) were revealed by multivariate analysis to be significant risk factors for CMV antigenemia. Grade II-IV aGVHD (P=.02) and grade 3-4 diarrhea before engraftment (P=.04) were revealed to be risk factors for CMV disease. The present study is the first study to show that severe diarrhea before engraftment is a significant risk factor for CMV disease. In summary, risk of CMV disease was significantly decreased in patients without severe mucosal injury of the gut because of the conditioning regimen before engraftment. Biol Blood Marrow Transplant 15: 679-685 (2009) (C) 2009 American Society for Blood and Marrow Transplantation
  • Matthias Schmidt, Elisabeth Sievers, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G. H. Schmidt-Wolf
    BRITISH JOURNAL OF HAEMATOLOGY 144 5 796 - 798 2009年03月 [査読有り][通常論文]
  • Mitsufumi Nishio, Tomoyuki Endo, Katsuya Fujimoto, Satoshi Yamamoto, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Ikumi Kasahara, Norihiro Sato, Takao Koike
    EUROPEAN JOURNAL OF HAEMATOLOGY 82 2 143 - 147 2009年02月 [査読有り][通常論文]
     
    Recent studies have indicated that patients who receive stem cell transplantation (SCT) and rituximab demonstrate an increased risk of developing hypogammaglobulinemia. Such hypogammaglobulinemia has been found to be due to delayed recovery of memory B cells with an abnormal cell marker expression and impaired immunoglobulin production in vitro. However, no predictive factors for the levels of immunoglobulin after autologous SCT and rituximab therapy have been reported. The aim of this study is to clarify the relationships between the FCGR3A-158V/F genotype and the levels of serum immunoglobulin after SCT. A total of 24 non-Hodgkin's lymphoma (NHL) patients received autologous SCT with an adjuvant rituximab. The FCGR3A-158V/F genotype was determined in these patients. We also included ten NHL patients who received an identical conditioning regimen and autologous SCT but no rituximab as control patients. The levels of IgG were significantly lower in FCGR3A-158F homozygous patients (n = 9) in comparison to those in FCGR3A-158V carriers (n = 15). Moreover, the levels of IgG and IgA of FCGR3A-158F homozygous patients, but not those of FCGR3A-158V carriers, were significantly lower than those of control patients. The genotype of FCGR3A determines not only the response to rituximab, but also the levels of immunoglobulin after SCT and an adjuvant rituximab.
  • Akio Shigematsu, Takeshi Kondo, Satoshi Yamamoto, Junichi Sugita, Masahiro Onozawa, Kaoru Kahata, Tomoyuki Endo, Soichi Shiratori, Shuichi Ota, Masato Ohara, Kentaro Wakasa, Mutsumi Takahata, Yukari Takeda, Junji Tanaka, Satoshi Hashino, Mitsufumi Nishio, Takao Koike, Masahiro Asaka, Masahiro Imamura
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 14 5 568 - 575 2008年05月 [査読有り][通常論文]
     
    We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide, (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI). The median age of the patients was 26 years. Thirteen patients underwent transplantation from HLA-matched related donors (MRD), 18 patients underwent transplantation from HLA-matched unrelated donors (MUD), and 6 patients underwent transplantation from HLA-mismatched donors (MMD). Thirty-two patients received bone marrow and 4 patients received peripheral blood stem cells. Ten patients were Philadelphia chromosome-positive (Ph+) and 35 patients were in complete remission (CR) at transplantation. All of the patients achieved engraftment, and grade 3 organ toxicity before engraftment occurred in 27 patients. Grade H-M acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively. No patient developed grade IV acute GVHD (aGVHD) or died of GVHD. At median follow-up of 35.1 months, 32 patients were alive and all Ph+ patients were alive. Three patients died of relapse and 2 died of transplant-related mortality (TRM). The actuarial 3-year overall survival (OS) rate, relapse rate, and TRM rate were 89.2%, 8.1%, and 5.4%, respectively. Non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival. Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival. (C) 2008 American Society for Blood and Marrow Transplantation.
  • Tetsuya Fukuda, Liguang Chen, Tomoyuki Endo, Li Tang, Desheng Lu, Jariuario E. Castro, George F. Widhopf, Laura Z. Rassenti, Mark J. Cantwell, Charles E. Prussak, Dennis A. Carson, Thomas J. Kipps
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 105 8 3047 - 3052 2008年02月 [査読有り][通常論文]
     
    We examined the sera of six patients before and after i.v. infusions of autologous chronic lymphocytic leukemia (CLL) cells transduced ex vivo with an adenovirus encoding CD154 (Ad-CD154). Five patients made high-titer antibodies against adenovirus and three made IgG reactive with a leukemia-associated surface antigen, which we identified as ROR1. Anti-ROR1 antibodies were not detected in the sera of untreated patients. We generated anti-ROR1 mAbs and found they reacted specifically with the CLL cells of all patients, but not with nonleukemic leukocytes, a wide variety of normal adult tissues, or blood mononuclear cells, including CD5(+) B cells of healthy adults. ROR1 could bind Wnt5a, which induced activation of NF-kappa B when coexpressed with ROR1 in HEK293 cells and enhanced the survival of CLL cells in vitro, an effect that could be neutralized by posttreatment anti-ROR1 antisera. We conclude that patients with CLL can break immune tolerance to ROR1, which is an oncofetal surface antigen and survival-signaling receptor in this neoplastic disease.
  • Takami A, Teshima T, Ushizaki K, Taniguchi T, Endo T, Sakurai H, Nakao S
    BONE MARROW TRANSPLANTATION 41 1 S229  2008年 [査読有り][通常論文]
     
    34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, ITALY, MAR 30-APR 02, 2008
  • Mitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, Tomoyuki Endo, Toshiya Sakai, Masato Obara, Kohki Kumano, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Norihiro Sato, Kazuki Koizumi, Masaya Mukai, Takao Koike
    BRITISH JOURNAL OF HAEMATOLOGY 137 4 349 - 354 2007年05月 [査読有り][通常論文]
     
    Recent studies have indicated that patients who received rituximab as an adjuvant to stem cell transplantation (SCT) demonstrated an increased risk of developing severe hypogammaglobulinaemia, which was found to be a result of delayed recovery of CD27 positive memory B cells and impaired isotype expression. It appears that rituximab influences both the quantity and quality of B-cell redistribution. Precisely how the B-cell repertoire regenerates after anti-CD20-mediated transient B-cell depletion in patients with non-Hodgkin lymphoma (NHL) remains to be elucidated. This study performed a phenotypical analysis of B cells in 17 NHL patients who received rituximab as an adjuvant to autologous SCT. The median period after final administration of rituximab was 36 months (range, 12-43 months). Surface antigen expression of CD27, CD40 and CD80 in NHL patients was statistically significantly different from healthy controls (n = 14). Moreover, B cells from NHL patients showed significantly impaired IgG and IgA production upon engagement of surface immunoglobulin receptors in the presence of interleukin (IL)-2, IL-10 and CD40 ligand in comparison with samples from healthy controls. The delayed recovery of memory B cells with an abnormal cell marker expression and function demonstrates that naive B cells may fail to differentiate into plasma cells, resulting in hypogammaglobulinaemia after autologous SCT and rituximab therapy.
  • Masahiko Shigemura, Takanori Moriyama, Hitoshi Shibuya, Masato Obara, Tomoyuki Endo, Satoshi Hashino, Hiroshi Yokouchi, Masahiro Asaka, Chikara Shimizu, Hitoshi Chiba, Masaharu Nishimura
    Clinica Chimica Acta 380 1-2 254  2007年05月01日 [査読有り][通常論文]
  • Masahiko Shigemura, Takanori Moriyama, Hitoshi Shibuya, Masato Obara, Tomoyuki Endo, Satoshi Hashino, Hiroshi Yokouchi, Masahiro Asaka, Chikara Shimizu, Hitoshi Chiba, Masaharu Nishimura
    CLINICA CHIMICA ACTA 376 1-2 121 - 125 2007年02月 [査読有り][通常論文]
     
    Background: There have been several reports describing a notable hyperamylasaemia in patients with multiple myeloma. Such amylase-producing myelomas have been mainly described in the context of concomitant salivary-type hyperamylasaemia, with sialyl salivary-type amylase identified in a portion of those cases. We investigated the incidence of the production of sialyl salivary-type amylase in serum of multiple myeloma patients. Methods: Eleven patients (6 male and 5 female) who had been diagnosed as having multiple myeloma were enrolled in this study. Sialyl salivary-type amylase was detected by isoamylase electrophoresis and HPLC analysis, and identified by detecting either abnormal neuraminidase-sensitive band through isoamylase electrophoresis or abnormal extra-elution peak of amylase by means of HPLC analysis. Results: Sialyl salivary-type amylase was detected in 7 out of 11 (63.6%) patients. Median total amylase activity was 154 U/l (range 109-43020). Isoamylase electrophoretic patterns of patients' serum were normal in 5 patients (71.4%) out of 7 patients and salivary-dominant in 2 (50.0%) out of 4 patients. Conclusions: We consider that there is no significant relationship between total serum amylase level and amylase isoenzyme pattern in the incidence of production of sialyl salivary-type amylase with multiple myeloma. (c) 2006 Elsevier B.V. All rights reserved.
  • Tomoyuki Endo, Mitsufumi Nishio, Thomas Enzler, Howard B. Cottam, Tetsuya Fukuda, Danelle F. James, Michael Karin, Thomas J. Kipps
    BLOOD 109 2 703 - 710 2007年01月 [査読有り][通常論文]
     
    Chronic lymphocytic leukemia (CLL) B cells express BR3, the specific receptor for the B cell-activating factor of tumor necrosis factor family (BAFF). CLL cells also express 2 other receptors for BAFF, namely B-cell maturation antigen (BCMA) and the transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI), which also bind a proliferation-inducing ligand (APRIL). We found that signaling through BR3, but not BCMA or TACI, activated the alternative nuclear factor of kappa B (NF-kappa B) pathway in CLL cells, whereas signaling through BCMA/ TACI induced activation of the canonical NF-kappa B pathway. Blocking BR3 did not inhibit the capacity of BAFF to support CLL cell survival in vitro. On the other hand, specifically blocking the canonical NF-kappa B pathway with LITC, an inhibitor of I kappa B kinase beta (IKK beta), or transfection of CLL cells with the I kappa B alpha super-repressor, blocked the capacity of BAFF and APRIL to promote CLL cell survival in vitro. This contrasts what is found with normal blood B cells, which apparently depend on activation of the alternative NF-kappa B pathway for BAFF-enhanced survival. These findings suggest that inhibitors of protein kinase IKK beta, which is required for activation of the canonical NF-kappa B pathway, might have a therapeutic role in this disease. (c) 2007 by The American Society of Hematology
  • Mitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, Tomoyuki Endo, Toshiya Sakai, Masato Obara, Kohki Kumano, Koichiro Minauchi, Keisuke Yamaguchi, Yukari Takeda, Norihiro Sato, Kazuki Koizumi, Masaya Mukai, Takao Koike
    EUROPEAN JOURNAL OF HAEMATOLOGY 77 3 226 - 232 2006年09月 [査読有り][通常論文]
     
    Objectives: Some studies have indicated patients who received rituximab as adjuvant to stem cell transplantation had an increased risk of developing severe hypogammaglobulinemia. The mechanism of this hypogammaglobulinemia is unknown, although investigators have hypothesized a further delay in the B-cell recovery as one potential etiology. The aim of this study is to clarify the mechanism(s) of this hypogammaglobulinemia. Methods: A total of 14 patients with high-risk CD20(+) lymphoma underwent an autologous peripheral blood stem cell transplantation (APBSCT). After a hematological recovery, rituximab was given weekly for up to four doses as an adjuvant therapy. Results: After a median follow up of 33.5 months, we found six patients (group A) who had hypogammaglobulinemia, while the eight other patients (group B) had normal serum immunoglobulin levels. A phenotypical analysis revealed that group A patients had already achieved B-cell recovery. However, we found a severe delay in the recovery of CD27(+) memory B cells, especially in the IgD(-)/CD27(+) switched populations in group A, but CD27 negative naive B-cells reverted to a normal range in both groups. Consistent with this, reverse transcriptase-polymerase chain reaction studies with peripheral blood mononuclear cells revealed that most patients in group A lacked more than two classes of isotype transcripts. Conclusions: Abnormal repertoires and impaired isotype expression are seen in patients with common variable immunodeficiency, these data suggested that rituximab after APBSCT can affect not only the B-cell quantities, but also the recovery of the B-cell repertoires.
  • T Hashimoto, M Nishio, T Sakai, K Fujimoto, N Sato, T Endo, T Koike
    CLINICAL INFECTIOUS DISEASES 42 11 1653 - 1655 2006年06月 [査読有り][通常論文]
  • M Nishio, T Endo, K Fujimoto, N Sato, T Sakai, M Obara, K Kumano, K Minauchi, T Koike
    EUROPEAN JOURNAL OF HAEMATOLOGY 75 6 527 - 529 2005年12月 [査読有り][通常論文]
  • A Takami, H Okumura, H Yamazaki, M Kami, SW Kim, H Asakura, T Endo, M Nishio, K Minauchi, K Kumano, N Sugimori, S Mori, Y Takemoto, S Shimadoi, J Ozaki, Y Takaue, S Nakao
    INTERNATIONAL JOURNAL OF HEMATOLOGY 82 5 449 - 455 2005年12月 [査読有り][通常論文]
     
    To determine whether induction of graft-versus-host disease (GVHD) improves the outcome of acute relapsed leukemia after stem cell transplantation (SCT), we used high-close cytarabine (ara-C) followed by infusions of donor-derived buffy coats containing peripheral blood stem cells to treat 12 patients with relapsed leukemia. Donor lymphocyte infusion (DLI) was repeated at least twice over a 5-week interval for patients in whom grade II to IV acute GVHD did not develop after the first DLI. Grade II to IV acute GVHD developed in 4 (33%) of the patients. Chronic GVHD developed in 3 patients, 2 of whom had not experienced acute GVHD. Four (67%) of the 6 patients who developed grade II to IV acute and/or chronic GVHD after DLI responded, but none of the other 6 patients responded. Four (33%) of the patients (2 with acute myelogenous leukemia [AML] and 2 with acute lymphoblastic leukemia [ALL]) achieved complete remission lasting longer than 4 months after the first DLI, but 3 of them had relapses in bone sites. Of these 4 patients, 1 patient with AML and 2 with ALL were alive 8 to 27 months after DLI. These findings indicate that high-dose ara-C combined with megadose DLI may produce durable remission of acute leukemia that has relapsed after SCT when GVHD is induced. The low induction rate of GVHD and extramedullary relapse after remission is achieved with DLI are problems yet to be solved.
  • M Nishio, T Endo, N Tsukada, J Ohata, S Kitada, JC Reed, NJ Zvaifler, TJ Kipps
    BLOOD 106 3 1012 - 1020 2005年08月 [査読有り][通常論文]
     
    We examined expression of B cell-activating factor of the tumor necrosis factor (TNF) family (BAFF) and a proliferation-inducing ligand (APRIL) on chronic lymphocytic leukemia (CLL) B cells and nurselike cells (NLCs), which differentiate from CD14(+) cells when cultured with CLL B cells. NLCs expressed significantly higher levels of APRIL than monocytes and significantly higher levels of BAFF and APRIL than CLL B cells. Also, the viability of CLL B cells cultured with NLCs was significantly reduced when CLL B cells were cultured with decoy receptor of B-cell maturation antigen (BCMA), which can bind both BAFF and APRIL, but not with BAFF receptor:Fc (BAFF-R:Fc), which binds only to BAFF. The effect(s) of BAFF or APRIL on leukemia cell survival appeared additive and distinct from that of stromal cell-derived factor-1 alpha (SDF1 alpha), which in contrast to BAFF or APRIL induced leukemia cell phosphorylation of p44/42 mitogen-activated protein kinase (extracellular signal-regulated kinase-1/2 [ERK1/2]) and AKT. Conversely, BAFF and APRIL, but not SDF-1 alpha, induced CLL-cell activation of the nuclear factor-kappa B1 (NF-kappa B1) and enhanced CLL-cell expression of the antiapoptotic protein Mcl-1. However, BAFF, but not APRIL, also induced CLL-cell activation of NF-kappa B2. We conclude that BAFF and APRIL from NLCs can function in a paracrine manner to support leukemia cell survival via mechanisms that are distinct from those of SDF-1 alpha, indicating that NLCs use multiple distinct pathways to support CLL-cell survival.
  • H Goto, M Nishio, T Endo, N Sato, K Koizumi, K Fujimoto, T Sakai, K Kumano, M Obara, T Koike
    EUROPEAN JOURNAL OF HAEMATOLOGY 74 6 526 - 528 2005年06月 [査読有り][通常論文]
     
    Generalized subcutaneous tumors developed without any other sites of the disease in a Japanese woman. Skin biopsy revealed CD5(+) and CD20(+) atypical diffuse large cells infiltrating subcutaneous tissues. The diagnosis was CD5(+) primary cutaneous diffuse large B-cell lymphoma. Tumor-specific PCR showed the existence of malignant cells in the peripheral blood and bone marrow. After three cycles of chemotherapy, she was remained in partial remission. Peripheral blood stem cells (PBSC) were harvested after the fourth cycles of chemotherapy combined with rituximab for in vivo purging. The contamination of tumor cells in PBSC was negative with PCR. She then underwent autologous peripheral blood stem cell transplantation using purged PBSC and has remained in complete remission for the past 24 month.
  • T Nomura, R Abe, K Fujimoto, T Endo, H Shimizu, T Koike
    AIDS 18 18 2446 - 2448 2004年12月 [査読有り][通常論文]
  • T Endo, N Sato, K Koizumi, M Nishio, K Fujimoto, S Yamamoto, T Sakai, T Bohgaki, K Sawada, T Koike
    CYTOTHERAPY 6 4 337 - 343 2004年08月 [査読有り][通常論文]
     
    Background CD34(+) cell-selected autologous PBSC transplantation (CD34(+) APBSCT) is a procedure used for the treatment of patients with malignant disease that is intended to eliminate residual tumor cells from autologous grafts. However, frequent infectious complications after CD34(+) APBSCT can occur. A delay of recovery of the absolute number of CD4(+) T cells after transplantation was reported to be one disadvantageous factor. As data on T-cell function after CD34(+) APBSCT are scanty, we analyzed changes in T-helper cell 1 (Th1) and T-helper cell 2 (Th2) after CD34(+) APBSCT to evaluate immune reconstitution. Methods Twelve patients underwent APBSCT (CD34(+) APBSCT group, n = 4, and unselected APBSCT, n = 8). Peripheral blood (PB) samples were obtained at 2, 4, 8, 12 and 16 weeks after the transplantation. The dynamics of the Th1 and Th2 were analyzed at a single-cell level, using flow cytometry. Results In the CD34(+) APBSCT group, not only the absolute count of CD4(+) T cells but also the proportion of Th1 cells in CD4(+) T cells and the ratio of Th1 to Th2 after transplantation were significantly decreased at 2 and 4 weeks after transplantation compared with findings in the unselected APBSCT group. Discussion We suggest that higher rates of infectious complications after CD34(+) APBSCT may be due to the inability of residual T cells from the CD34(+) cell selection to generate mature T cells that function adequately against infection. Although further study would be required, our preliminary data provide some information on the immune reconstitution after CD34(+) APBSCT and differentiation of T lymphocytes into Th1 and Th2 in vivo.
  • T Endo, N Sato, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Kumano, M Obara, K Minauchi, T Koike
    AMERICAN JOURNAL OF HEMATOLOGY 76 3 279 - 282 2004年07月 [査読有り][通常論文]
     
    We report a patient with a relapsed in bone marrow of extremities after allogeneic peripheral blood stem cell transplantation for acute lymphoblastic leukemia (ALL). The patient complained of pain in the right upper arm and left leg 15 months after transplantation. Magnetic resonance imaging (MRI) and fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) showed abnormal findings in bone marrow of upper and lower extremities. There were no findings of relapse in aspirates from the sternum and iliac bone marrow. Biopsy specimen from the iliac bone marrow showed normocellular marrow without leukemic cells. Biopsy specimen from the right humerus revealed marked leukemic cell infiltration in the bone marrow. This is apparently the first case of localized relapse of ALL in bone marrow of extremities. Physicians should be aware of unusual relapse sites of leukemia after allogeneic stem cell transplantation. MRI and FDG-PET may be of value in detecting this type of relapse. (C) 2004 Wiley-Liss, Inc.
  • H Fukaya, WG Xiao, K Inaba, Y Suzuki, M Hirokawa, Y Kawabata, A Komatsuda, T Endo, H Kishimoto, G Takada, K Sawada
    EXPERIMENTAL HEMATOLOGY 32 5 450 - 460 2004年05月 [査読有り][通常論文]
     
    Objective. Tumor necrosis factor-alpha (TNF-alpha) inhibits erythropoiesis and enhances nonerythroid colony formation. The present study examines the nature of these nonerythroid cells and investigates their physiologic role in relation to erythroid progenitor cells. Materials and Methods. Highly purified human CD34(+) cells underwent erythroid differentiation in the presence of multiple cytokines, including stem cell factor (SCF), interleukin-3 (IL-3), and erythropoietin (EPO), with and without TNF-alpha. We enumerate colony-forming unit-erythroid (CFU-E) and glycophorin A (GPA; a specific marker for erythroid lineage) positive cells in semisolid phase as well as in liquid suspension culture. The character and roles of codeveloping nonerythroid cells in the presence of TNF-alpha were analyzed using fluorescent activating cell sorter, enzyme immunohistochemistry, and confocal microscopy. Results. TNF-alpha inhibited the generation of GPA(+) cells and conversely enhanced the generation of GPA(-) cells. The GPA(-) cells were comprised of cells with excentric cell shape and were positive for HLA class I, HLA class II, CD1a, CD4, CD11c, CD14, CD40, CD80, CD83, and CD86, but not for CD3, CD8, CD19, CD20, and CD56, indicating the codevelopment of dendritic cells (DC) along with erythroid differentiation. Developing DC/DC precursors were detected within 3 days of culture. Only in the presence of TNF-alpha did CD34(+) cells proliferate by forming aggregates where both GPA(+) and CD11c(+) DC/DC precursors were present. During culture period, immature CD11c(+) DC were capable of endocytosing damaged GPA(+) cells. Conclusions. GPA(-) cells cogenerated from human CD34(+) cells during erythroid differentiation in the presence of IL-3/SCF/EPO and TNF-alpha express DC phenotypes. The CD11c(+) DC subset physically and selectively associates with developing immature erythroid cells and damaged self-GPA(+) cells and then obtains and captures self-substances. (C) 2004 International Society for Experimental Hematology. Published by Elsevier Inc.
  • T Endo, N Sato, Y Mogi, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Kumano, M Obara, H Ikeda, T Koike
    BONE MARROW TRANSPLANTATION 33 7 703 - 707 2004年04月 [査読有り][通常論文]
     
    We mobilized peripheral blood stem cells ( PBSC) following CHOP plus rituximab ( CHOP- R) therapy, and compared with the findings following CHOP therapy without rituximab. All patients were given G- CSF starting from day 11 after CHOP therapy. Patients in the CHOP-R group ( n = 8) were given rituximab on day 12. Target CD34(+) cells number was collected in a single leukapheresis on day 14, from all the eight patients in the CHOP- R group. PBSC mobilization kinetics, CD34(+) cells yield and colony- forming ability in the graft collection, toxicity during mobilization, and engraftment after transplantation of CHOP- R group were not significantly different from those in the CHOP group ( n = 8). In all patients given CHOP- R therapy, CD20(+) cells and immunoglobulin heavy chain ( IgH) rearrangement in the graft collection were undetectable by flow-cytometric analysis and Southern blot analysis, respectively, but with PCR analysis two of eight grafts were positive for IgH rearrangement. While further studies are needed to evaluate the efficacy of purging and the outcome of patients undergoing autologous transplantation, CHOP- R therapy can be safely and effectively used in the mobilization phase of PBSC collection, without excess clinical toxicity or deleterious effect on PBSC mobilization kinetics or engraftment time.
  • K Koizumi, K Fujimoto, Y Haseyama, T Endo, M Nishio, K Yokota, T Itoh, K Sawada, T Koike
    EUROPEAN JOURNAL OF HAEMATOLOGY 72 2 140 - 144 2004年02月 [査読有り][通常論文]
     
    The prognosis of nasal natural killer (NK)/T-cell lymphoma with cutaneous involvement especially is morbid despite intensive chemotherapy and radiotherapy. We treated a 52-yr-old Japanese woman with cutaneous dissemination of nasal NK/T-cell lymphoma. Six cycles of chemotherapy, irradiation to skin lesion were administered and complete remission (CR) was attained. High-dose chemotherapy (HDC; etoposide 750 mg/m(2) x 2 d, cyclophosphamide 60 mg/kg x 2 d, total body irradiation 12 Gy two daily fractions x 3 d) followed by CD34(+)-selected autologous peripheral blood stem cell transplantation (CD34(+)-APBSCT) was then prescribed. Complete remission (CR) was obtained and she has been free of disease for 34 months since CD34(+)-APBSCT. We suggest that marrow-ablative chemotherapy facilitated by autologous stem cell transplantation should be considered part of the primary therapy for subjects with a poor prognosis for nasal NK/T-cell lymphoma with cutaneous involvement.
  • T Endo, S Nakao, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Kumano, M Obara, T Koike
    ANNALS OF HEMATOLOGY 83 2 114 - 116 2004年02月 [査読有り][通常論文]
     
    A 30-year-old Japanese woman who underwent nonmyeloablative stem cell transplantation from her HLA-matched sister developed autoimmune hemolytic anemia (AIHA). There was proliferation of EBV-DNA in her peripheral blood and monoclonal gammopathy, both predictive factors of post-transplant lymphoproliferative disorder (PTLD). As conventional immunosuppressive therapy for AIHA could lead to overt PTLD, we decided to give her rituximab 375 mg/m(2) once weekly for a total of four doses. After this therapy, both her AIHA and monoclonal gammopathy were resolved and EBV-DNA became undetectable. Rituximab therapy deserves consideration for treatment of post-allogeneic stem cell transplant patients with AIHA, especially for patients who cannot be given immunosuppressive therapy.
  • M Shigemura, T Moriyama, T Endo, H Shibuya, H Suzuki, M Nishimura, H Chiba, K Matsuno
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE 42 6 677 - 680 2004年 [査読有り][通常論文]
  • K Kawakubo, T Endo, K Koizumi, M Nishio, K Fujimoto, T Sakai, K Sawada, T Koike
    EUROPEAN JOURNAL OF HAEMATOLOGY 71 2 124 - 127 2003年08月 [査読有り][通常論文]
     
    A 57-yr-old woman with multiple myeloma underwent tandem autologous peripheral blood stem cell transplantation (APBSCT). Fever, anemia, and thrombocytopenia, followed by the proliferation of granular lymphocytes in the peripheral blood occurred, after a second APBSCT. Clonal rearrangement of the T-cell receptor was detected using Southern blot analysis of peripheral blood samples. Granular lymphocyte proliferative disorders (GLPD) were diagnosed. After steroid therapy, the symptoms resolved. Lymphocytosis did not recur after the discontinuation of steroids. There have been a few reports of GLPD after solid organ and allogeneic hematopoietic stem cell transplantations. We report a first case of GLPD after APBSCT.
  • K Koizumi, S Nakao, Y Haseyama, H Kato, M Ohi, T Motohara, T Endo, K Sawada, T Koike
    ANNALS OF HEMATOLOGY 82 6 367 - 370 2003年06月 [査読有り][通常論文]
     
    Aplastic anemia has been a rare complication of thymic tumors documented in only a few cases. We now report that a previously healthy, 72-year-old woman had a well-differentiated squamous cell thymic carcinoma and severe aplastic anemia, as detected on a simultaneous basis. After extirpation of the thymic carcinoma, hematological recovery was achieved. While cyclosporine (CyA), prednisolone (PSL), and methenolone improved hematological data even more, a partial and stable remission has been sustained for 22 months. The patient's serum prior to the surgery had a suppressive effect on the formation of colonies of erythroid and nonerythroid colonies, as determined using the patient's bone marrow cells and compared with the patient's serum after the surgery and normal AB serum. This case report concerns a patient in whom we observed simultaneous occurrence of a thymic tumor and a sever marrow aplasia for which we describe our therapeutic approach.
  • WG Xiao, K Koizumi, M Nishio, T Endo, M Osawa, K Fujimoto, Sato, I, T Sakai, T Koike, K Sawada
    EXPERIMENTAL HEMATOLOGY 30 11 1238 - 1247 2002年11月 [査読有り][通常論文]
     
    Objective. The inhibitory effects of tumor necrosis factor-alpha (TNF-alpha) on cytokine-induced proliferation and differentiation of normal human erythroid progenitors have been characterized extensively, yet little is known about the maturation level of erythroid progenitors that are sensitive to TNF-alpha or of the expression of TNF receptors (TNFRs) in erythroid lineage. The aim of this study was to determine the extent to which human erythroid progenitor cells are sensitive to TNF-alpha, and to relate this to the expression of TNFRs in the erythroid lineage. Materials and Methods. Highly purified human CD34(+) cells underwent erythroid differentiation, with or without TNF-alpha. We used colony assay as well as a method by which colony-forming unit-erythroid (CFU-E) and glycophorin A (GPA; a specific marker for erythroid lineage) positive cells can be generated in liquid phase from purified human CD34(+) cells in the presence of multiple cytokines, including stem cell factor (SCF), interleukin-3 (IL-3), and erythro-poietin (EPO). During erythroid differentiation of CD34(+) cells, TNFRs expression were monitored. Results. TNF-alpha inhibited the generation of GPA(+) cells by CD34(+) cells as well as the proliferative capacity of GPA(+) cells supported by EPO, IL-3, and SCF. Erythroid progenitors became resistant to the inhibitory effect of TNF-alpha as they matured. The detectable expression of TNFR-I was transient in the early phase of erythroid differentiation, whereas TNFR-II was expressed through the entire course of erythroid differentiation of CD34(+) cells. Conclusions. TNF-alpha suppresses erythropoiesis by inhibiting the generation of GPA(+) cells derived from CD34(+) cells as well as by inhibiting the proliferative capacity of GPA(+) cells. Although the presence of TNFRs does not directly indicate that the receptor(s) mediates death signaling, altered expression of TNFRs depending on the level of maturation may imply altered sensitivities to TNF-alpha in various stage of erythroid progenitors. (C) 2002 International Society for Experimental Hematology. Published by Elsevier Science Inc.
  • T Endo, A Odb, Satoh, I, Y Haseyama, M Nishio, K Koizumi, H Takashima, K Fujimoto, Y Amasaki, H Fujita, T Koike, K Sawada
    EXPERIMENTAL HEMATOLOGY 29 7 833 - 841 2001年07月 [査読有り][通常論文]
     
    Objective. It has been reported that stem cell factor (SCF) promotes cell survival in primary cultured human erythroid colony-forming cells (ECFC), Given the heterogeneous nature of ECFC, which may affect interpretation of the data, we purified c-kit(+) ECFC and investigated the specificity and mechanisms of the anti-apoptotic effects of SCF on these cells. Materials and Methods. Glycophorin A(+) (GPA(+)) c-kit(+) cells were purified from primary cultured ECFC derived from purified human CD34(+) cells. The GPA(+)c-kit(-) and nonerythroid cells were generated from the same CD34(+) cells. Apoptosis of ECFC was investigated in the absence or presence of SCF and erythropoietin (EPO) in serum-free medium. DNA fragmentation was measured with enzyme linked immunosorbent assay for oligonucleosome-sized DNA, gel electrophoresis, and annexin V labeling. Characterization of expanded cells and enriched cells was performed using multiparameter flow cytometry, For Akt assay, cells were lysed and the cleared lysates subjected to SDS-PAGE followed by Western blotting. Results. In GPA(+)c-kit(+) cells, deprivation of cytokine caused rapid DNA fragmentation within 4 hours that reached a maximum at 6 hours. This was partially but clearly prevented by SCF or EPO, In contrast, no significant DNA fragmentation was seen in GPA(+)c-kit(-) and nonerythroid cells within 24 hours. PP2, a specific Src family kinase inhibitor, but not its inactive analogue PP3, reversed the anti-apoptotic effects of SCF, PP2 also inhibited SCF-induced phosphorylation of Akt, Conclusions. These data indicate that SCF protects purified human GPA(+)c-kit(+) cells from apoptosis and suggest that kit-mediated Src kinase activation is involved in Akt activation and cell survival. (C) 2001 International Society for Experimental Hematology. Published by Elsevier Science Inc.
  • T Endo, T Sakai, K Fujimoto, S Yamamoto, H Takashima, Y Haseyama, M Nishio, K Koizumi, T Koike, K Sawada
    BONE MARROW TRANSPLANTATION 27 4 433 - 436 2001年02月 [査読有り][通常論文]
     
    Hepatitis B virus (HBV) reactivation, a well-known complication in immunosuppressed patients, can give rise to acute hepatitis and even fatal fulminant hepatitis. Three Japanese males with non-Hodgkin's lymphoma (NHL) who were carriers of HBV received high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT). To prevent HBV reactivation, all received oral lamivudine (150 mg/day), a nucleoside analogue, at the start of chemotherapy, All were treated at full-dose intensity, including corticosteroids, without modification of treatment regimens. All three patients completed the total course of chemotherapy and PBSCT, with no signs of HBV reactivation. Peripheral blood stem cell (PBSC) harvests and hematological recoveries after transplantation were not affected by lamivudine, which was continued for at least 16 weeks after transplantation. HBV-DNA and DNA polymerase levels remained negative/normal after discontinuation of lamivudine. Lamivudine effectively inhibits HBV replication and has few serious adverse effects, particularly those related to hematopoiesis. Thus, prophylactic use of lamivudine from initiation of chemotherapy deserves consideration in the treatment of HBV carriers who require immunosuppressive chemotherapy, and may prevent HBV reactivation.
  • K Koizumi, M Nishio, T Endo, H Takashima, Y Haseyama, K Fujimoto, S Yamamoto, N Sato, K Ikebuchi, H Ikeda, T Koike, K Sawada
    BONE MARROW TRANSPLANTATION 26 7 787 - 793 2000年10月 [査読有り][通常論文]
     
    Isolation of large numbers of human peripheral blood CD34(+) cells could lead to therapeutic applications, including purging of malignant cells from blood cell transplantations, purging of T cells from allogeneic bone marrow, and even blood cell transplantation. This procedure has limitations if there are not sufficient numbers of progenitor cells in the leukapheresis concentrates available for selection after detection of tumor cells in apheresis products. Use of frozen/thawed peripheral blood mononuclear cell (PBMC) samples would make feasible pooling of two or even more stem cell harvests collected at different time points and the total number of CD34(+) progenitor cells available would increase. We established an efficient method for purification of CD34(+) cells from cryopreserved apheresis products, using a nylon-fiber syringe system and immunomagnetic microspheres. We compared purity, recovery rate and clonogenicity of CD34(+) cells purified from fresh (n = 22) and cryopreserved apheresis products (n = 14), using a nylon-fiber syringe system and immunomagnetic microspheres, The purity of CD34(+) cells from cryopreserved products was less than that from fresh products (85.9 +/- 14.4% vs 94.6 +/- 10.0%), but the recovery rate of CD34(+) cells and colony-forming cells was comparable between fresh and cryopreserved products. One patient underwent grafting with peripheral blood CD34(+) cells selected after freezing, with good success. Therefore, these cells are capable of rapidly reconstituting hematopoiesis after high-dose chemotherapy.
  • M Nishio, K Koizumi, T Endo, H Takashima, Y Haseyama, K Fujimoto, S Yamamoto, H Kobayashi, T Koike, K Sawada
    BONE MARROW TRANSPLANTATION 25 12 1315 - 1317 2000年06月 [査読有り][通常論文]
     
    Generalized multiple cutaneous tumors developed in a 60-year-old Japanese man. Skin biopsy revealed atypical large T lymphocytes infiltrating the dermis, CD30 staining was negative in the tumor cells. The diagnosis of CD30-negative cutaneous large T cell lymphoma was made. Axial and inguinal lymphadenopathy was present, but there was no evidence of bone marrow involvement. Seven cycles of chemotherapy and local electron beam irradiation were administered and complete remission (CR) was attained. As CD30-negative cutaneous large T cell lymphoma has a poor prognosis despite intensive chemotherapy, high-dose chemotherapy followed by CD34(+)-selected autologous peripheral blood stem cell transplantation (CD34(+)-APBSCT) was prescribed. The clinical course after CD34(+)-selected APBSCT was complicated with CMV infection occurring twice but administration of ganciclovir resolved the symptoms. He has remained in CR for 16 months after CD34(+)-APBSCT. This appears to be the first case report of CD34(+)-APBSCT in a patient with CD30-negative cutaneous large T cell lymphoma.
  • M Nishio, K Sawada, K Koizumi, T Tarumi, H Takano, T Endo, H Takashima, H Hashimoto, Y Haseyama, H Kobayashi, T Koike
    BONE MARROW TRANSPLANTATION 22 12 1211 - 1214 1998年12月 [査読有り][通常論文]
     
    Localized cutaneous nontender nodules appeared on the back of a 52-year-old Japanese woman. Skin biopsy revealed atypical large T-lymphocytes infiltrating the dermis, CD30 staining was negative in tumor cells. The diagnosis was CD30-negative cutaneous large T cell lymphoma. There was no evidence of peripheral lymphadenopathy or bone marrow involvement. Six cycles of induction chemotherapy were administered and a complete clinical remission (CCR) was attained, Local irradiation was not given. As the clinical course of CD30-negative cutaneous large T cell lymphoma is recurrent and often incurable with conventional chemoradiotherapy, she received high-dose chemotherapy without total body irradiation (TBI) followed by unpurged autologous peripheral blood stem cell transplantation (APBSCT), A relapse in the skin followed 40 days after APBSCT, but tumor cells transformed into a CD30-positive anaplastic large cell lymphoma (ALCL), We question the need for TBI in conditioning and for purged stem cells for APBSCT in patients with high risk cutaneous lymphomas.

その他活動・業績

  • Seitaro Terakura, Tetsuya Nishida, Masashi Sawa, Tomonori Kato, Kotaro Miyao, Yukiyasu Ozawa, Tatsunori Goto, Akio Kohno, Kazutaka Ozeki, Yasushi Onishi, Noriko Fukuhara, Nobuharu Fujii, Hisayuki Yokoyama, Masanobu Kasai, Hiroatsu Iida, Nobuhiro Kanemura, Tomoyuki Endo, Hiroatsu Ago, Makoto Onizuka, Satoshi Iyama, Yuichiro Nawa, Mika Nakamae, Yasuyuki Nagata, Shingo Kurahashi, Yasuo Tomiya, Atsumi Yanagisawa, Ritsuro Suzuki, Yachiyo Kuwatsuka, Yoshiko Atsuta, Koichi Miyamura, Makoto Murata Bone marrow transplantation 2020年03月16日 [査読無し][通常論文]
     
    A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors (UD) and cord blood (CB) on outcomes in adult acute leukemia (AL) and myelodysplastic syndrome (MDS). Between 2007 and 2015, 231 transplant-eligible patients were registered for a phase 2 study of alternative donor transplantation. After registration, a sufficient time period was given to find appropriate UD. Patients received CB transplantation (CBT) if an appropriate UD was unavailable. In total, 119 patients received CBT (106 AL and 13 MDS) and 91 patients received UD transplantation (UDT) (86 AL and 5 MDS). The median age was 39 years in both groups. The primary objective was overall survival (OS); secondary objectives included cumulative incidences of non-relapse mortality (NRM) and relapse, and disease-free survival. Diagnosis, disease status at transplantation, refined disease risk index, and hematopoietic cell transplant-specific comorbidity index did not differ between UDT and CBT. In multivariate analyses, graft source was not a significant risk factor for all objectives. In adjusted analyses, UDT and CBT showed similar OS, NRM, and relapse in this prospective study. CB can be a comparable alternative stem cell source to UD by achieving a timely transplant.
  • AMLにおけるWT1発現量と染色体・遺伝子異常の関連
    日高 大輔, 小野澤 真弘, 橋口 淳一, 宮下 直洋, 笠原 耕平, 藤澤 真一, 早瀬 英子, 岡田 耕平, 白鳥 聡一, 後藤 秀樹, 杉田 純一, 中川 雅夫, 加畑 馨, 橋本 大吾, 遠藤 知之, 山本 聡, 堤 豊, 長谷山 美仁, 永嶋 貴博, 盛 暁生, 太田 秀一, 酒井 基, 石原 敏道, 今井 陽俊, 宮城島 拓人, 柿木 康孝, 黒澤 光俊, 小林 一, 岩崎 博, 清水 力, 近藤 健, 豊嶋 崇徳 臨床血液 59 (7) 964 -964 2018年07月 [査読無し][通常論文]
  • ステロイド抵抗性急性移植片対宿主病に対するヒト間葉系幹細胞療法の後方視的解析
    白鳥 聡一, 早瀬 英子, 岡田 耕平, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 中川 雅夫, 加畑 馨, 橋本 大吾, 遠藤 知之, 近藤 健, 豊嶋 崇徳 日本輸血細胞治療学会誌 64 (2) 452 -452 2018年04月 [査読無し][通常論文]
  • Hiroyuki Nakamura, Shinsuke Yasuda, Atsushi Noguchi, Toshio Odani, Yuichiro Fujieda, Masaru Kato, Kenji Oku, Junichi Sugita, Toshiyuki Bohgaki, Tomoyuki Endo, Takanori Teshima, Tatsuya Atsumi ARTHRITIS & RHEUMATOLOGY 69 2017年10月 [査読無し][通常論文]
  • 脳生検により診断した進行性多巣性白質脳症の長期生存例
    佐藤 翔紀, 白井 慎一, 高橋 育子, 矢部 一郎, 遠藤 知之, 豊嶋 崇徳, 山口 秀, 桑原 健, 畑中 佳奈子, 松野 吉宏, 今村 顕史, 三浦 義治, 中道 一生, 西條 政幸, 佐々木 秀直 NEUROINFECTION 22 (2) 244 -244 2017年09月 [査読無し][通常論文]
  • IgA型ALアミロイドーシスに線状IgA皮膚症を併発した1例
    山口 泰之, 氏家 英之, 大東 寛幸, 岩田 浩明, 村松 憲, 清水 宏, 遠藤 知之, 豊嶋 崇徳 日本皮膚科学会雑誌 127 (9) 2111 -2111 2017年08月 [査読無し][通常論文]
  • 杉山昂, 後藤了一, 川村典生, 腰塚靖之, 渡辺正明, 武冨紹信, 遠藤知之, 藤本勝也, 近藤健, 山下健一郎, 嶋村剛 北海道外科雑誌 62 (1) 96 2017年06月20日 [査読無し][通常論文]
  • A. Shigematsu, S. Ota, H. Goto, K. Minauchi, J. Sugita, D. Hashimoto, M. Obara, T. Endo, M. Imamura, T. Teshima, N. Kobayashi HAEMATOLOGICA 102 354 -354 2017年06月 [査読無し][通常論文]
  • 当院においてドナーリンパ球輸注を施行した34症例の検討
    石尾 崇, 立野 貴大, 笠原 耕平, 小杉 瑞葉, 白鳥 聡一, 岡田 耕平, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 遠藤 知之, 近藤 健, 豊嶋 崇徳 日本輸血細胞治療学会誌 63 (2) 148 -149 2017年04月 [査読無し][通常論文]
  • HIV/HCV重複感染者に対するソホスブビルを投与(多施設共同研究)
    四柳 宏, 遠藤 知之, 塚田 訓久, 潟永 博之, 三田 英治, 菊地 正, 鯉渕 智彦, 木村 哲 感染症学雑誌 91 (臨増) 278 -278 2017年03月 [査読無し][通常論文]
  • Makoto Murata, Yoshinobu Maeda, Masayoshi Masuko, Yasushi Onishi, Tomoyuki Endo, Seitaro Terakura, Yuichi Ishikawa, Chisako Iriyama, Yoko Ushijima, Tatsunori Goto, Nobuharu Fujii, Mitsune Tanimoto, Hironori Kobayashi, Yasuhiko Shibasaki, Noriko Fukuhara, Yoshihiro Inamoto, Ritsuro Suzuki, Tadashi Matsushita, Yoshihisa Kodera, Hitoshi Kiyoi, Tomoki Naoe, Tetsuya Nishida BLOOD 128 (22) 2016年12月 [査読無し][通常論文]
  • 胆嚢炎症状を契機に発症したTAFRO症候群
    関根 隆博, 後藤 秀樹, 日高 大輔, 早瀬 英子, 小杉 瑞葉, 岡田 耕平, 白鳥 総一郎, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 遠藤 知之, 近藤 健, 豊嶋 崇徳 臨床血液 57 (12) 2608 -2608 2016年12月 [査読無し][通常論文]
  • 遠藤知之, 遠藤知之, 宮下直洋, 宮下直洋, 笠原耕平, 笠原耕平, 小杉瑞葉, 岡田耕平, 白鳥聡一, 後藤秀樹, 杉田純一, 小野澤真弘, 橋本大吾, 加畑馨, 藤本勝也, 藤本勝也, 近藤健, 橋野聡, 橋野聡, 豊嶋崇徳, 豊嶋崇徳 日本エイズ学会誌 18 (4) 439 -439 2016年11月20日 [査読無し][通常論文]
  • 肺胞蛋白症を合併し致死的な経過を辿った骨髄異形成症候群の1例
    大東 寛幸, 松川 敏大, 金谷 穣, 後藤 秀樹, 橋本 大吾, 加畑 馨, 遠藤 知之, 田中 伸哉, 豊嶋 崇徳 臨床血液 57 (11) 2398 -2398 2016年11月 [査読無し][通常論文]
  • HIV感染症合併血友病患者に対するMRIによる脳スクリーニングの意義
    遠藤 知之, 宮下 直洋, 笠原 耕平, 小杉 瑞葉, 岡田 耕平, 白鳥 聡一, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 近藤 健, 橋野 聡, 豊嶋 崇徳 日本エイズ学会誌 18 (4) 439 -439 2016年11月 [査読無し][通常論文]
  • 多職種で連携して診療にあたったHIV合併妊娠管理についての検討
    金川 明功, 小島 崇史, 山田 崇弘, 長 和俊, 遠藤 知之, 西村 あや子, 石川 聡司, 森川 守, 山田 俊, 近藤 健, 水上 尚典 北日本産科婦人科学会総会・学術講演会プログラム・抄録集 64回 145 -145 2016年09月 [査読無し][通常論文]
  • 当院における同種末梢血幹細胞採取の検討
    杉田 純一, 大東 寛幸, 橋口 淳一, 松川 敏大, 金谷 穣, 小杉 瑞葉, 松岡 里湖, 後藤 秀樹, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 遠藤 知之, 近藤 健, 豊嶋 崇徳 日本輸血細胞治療学会誌 62 (3) 490 -490 2016年06月 [査読無し][通常論文]
  • 【エイズの臨床 アップデート】 医療現場における曝露後予防
    遠藤 知之 アレルギー・免疫 23 (5) 702 -707 2016年04月 [査読無し][通常論文]
     
    HIV感染者数の増加と患者の高齢化に伴い、様々な施設においてHIV感染者と関わる必要性がでてきている。HIV感染者の診療に際しては、感染対策として特別な対応は必要なく、標準予防策の遵守が基本となる。針刺し等の血液・体液曝露の際には、速やかに抗HIV薬の予防内服を開始することで感染率をほぼゼロにすることができる。HIV曝露後予防の第一推奨薬はTenofovir/Emtricitabine(ツルバダ)とRaltegravir(アイセントレス)の2剤である。いざというときに慌てないために、曝露時の対応マニュアルを各施設で整備しておくことが重要である。(著者抄録)
  • 【すべての内科医のためのHIV感染症-長期管理の時代に】 HIV感染症にまつわるFAQ HIVに求められる感染対策
    遠藤 知之 内科 116 (5) 815 -819 2015年11月 [査読無し][通常論文]
     
    HIV感染者数の増加と生命予後改善に伴う患者の高齢化に伴い,さまざまな施設/診療科においてHIV感染者と関わる必要性が出てきている.HIV感染者の診療に際しては,感染対策として特別な対応は必要なく,標準予防策(standard precautions)の遵守が基本となる.HIVは,HBVやHCVと比較して感染力が弱いため,医療器具の消毒などもHBVのマニュアルに準じて行うことで十分である.針刺しなどの曝露事故の際には,速やかに抗HIV薬の予防内服を開始することで感染率を下げることができる.いざというときに慌てないために,曝露事故時の対応マニュアルなどを各施設で整備しておくことが重要である.(著者抄録)
  • Cardio-ankle vascular index(CAVI)を用いたHIV感染者の動脈硬化の評価とリスク因子の検討
    遠藤 知之, 宮下 直洋, 笠原 耕平, 渡部 恵子, 武内 阿味, 松川 敏大, 金谷 穣, 小杉 瑞葉, 松岡 里湖, 後藤 秀樹, 杉田 純一, 小野澤 真弘, 橋本 大吾, 加畑 馨, 藤本 勝也, 近藤 健, 橋野 聡, 豊嶋 崇徳 日本エイズ学会誌 17 (4) 392 -392 2015年11月 [査読無し][通常論文]
  • 初回ART導入におけるRaltegravirとDolutegravirの血液毒性への関与
    後藤 秀樹, 遠藤 知之, 藤本 勝也, 近藤 健, 加畑 馨, 橋本 大吾, 小野澤 真弘, 杉田 純一, 松川 敏大, 笠原 耕平, 宮下 直洋, 橋野 聡, 佐藤 典宏, 豊嶋 崇徳 日本エイズ学会誌 17 (4) 510 -510 2015年11月 [査読無し][通常論文]
  • 【危惧する感染症-院内感染防止対策-】 HIV感染症
    遠藤 知之 Surgery Frontier 22 (3) 209 -215 2015年09月 [査読無し][通常論文]
     
    わが国では、新規のHIV感染者/AIDS発症者数が、いまだ低下傾向を示していない。抗HIV薬の進歩にともない患者の生命予後が劇的に改善したこともあり、わが国におけるHIV感染者数は増え続けている。HIV感染者の診療に際しては、特別な対応は必要なく、スタンダードプリコーションの遵守が基本となる。HIVは、HBVやHCVと比較して感染力が弱いため、医療器具の消毒などもHBVのマニュアルに準じて行うことで十分である。針刺しなどの曝露事故の際には、すみやかに抗HIV薬を内服することにより感染率を下げることができる。いざという時に慌てないために、曝露事故時の対応マニュアルなどを各施設で整備しておくことが重要である。(著者抄録)
  • 当院におけるHIV感染者のビタミンDの検討
    遠藤 知之, 藤本 勝也, 南 昭子, 吉田 美穂, 竹村 龍, 渡部 恵子, 坂本 玲子, 武内 阿味, 近藤 健, 橋野 聡, 清水 力, 豊嶋 崇徳 日本エイズ学会誌 17 (1) 30 -35 2015年02月 [査読無し][通常論文]
     
    HIV感染者におけるビタミンDの充足率を把握し、骨密度低下と因果関係を評価した。方法は著者らの施設へ通院中のHIV患者118例(男性115例、女性3例、年齢24〜73歳、平均年齢43歳)を対象に、血清25水酸化ビタミンD[25(OH)D]を測定、そのうち100例でDXA法による骨塩量測定検査を行った。その結果、1)血清25(OH)Dの平均値は18.5±11.0ng/mlであり、ビタミンD不足(20〜29ng/dl)は24例(20.3%)、ビタミンD欠乏(20ng/dl以下)が79例(67.0%)にみられた。更にビタミンD高度欠乏(10ng/ml以下)は26例(22.0%)にみられ、ビタミンD正常(30ng/ml以上)は15例(12.7%)に過ぎなかった。2)100例におけるDXA法による骨塩定量測定では骨減少症は27例(27.0%)、骨粗鬆症は8例(8%)であった。3)このことからビタミンDの充足度と骨密度には有意な相関は認められなかったが、抗HIV療法を受けている症例では未治療の症例と比較して有意に骨密度が低下していた。4)多くのHIV患者でビタミンDが不足・欠乏していたが、骨密度低下の要因としてはビタミンD欠乏より抗HIV薬の影響が大きいと考えられた。以上より、HIV患者にビスホスフォネートを投与する際にはビタミンDの評価を行い、ビタミンDが低下・欠乏している症例に対するビタミンDの補充も必要と考えられた。
  • 当科におけるHCV/HIV重複感染症の現状と抗HCV療法
    荘 拓也, 中馬 誠, 常松 聖司, 佐藤 史幸, 佃 曜子, 寺下 勝巳, 中井 正人, 堀本 啓大, 須田 剛生, 夏井坂 光輝, 藤本 勝也, 遠藤 知之, 豊嶋 崇徳, 坂本 直哉 肝臓 55 (Suppl.1) A213 -A213 2014年04月 [査読無し][通常論文]
  • 北海道内のHIV感染症患者におけるHBV・HCV重複感染の現状
    藤本勝也, 遠藤知之, 吉田美穂, 竹村龍, 近藤健, 橋野聡, 須田剛生, 中馬誠, 後藤了一, センテノ田村恵子, 渡部恵子, 大野稔子, 石田禎夫, 大竹孝明, 宮城島拓人, 小林一, 堤豊, 三宅高義, 北川浩彦, 佐藤典宏, 豊嶋崇徳 日本エイズ学会誌 16 (1) 18 -27 2014年02月 [査読無し][通常論文]
  • 臨床 抗HIV療法 テノホビル/エムトリシタビン・ロピナビル/リトナビル内服例を現行レジメンとラルテグラビル・ダルナビル/リトナビルに無作為割付する多施設共同臨床試験
    西島 健, 潟永 博之, 遠藤 知之, 堀場 昌英, 古賀 道子, 内藤 俊夫, 井戸田 一朗, 鄭 真徳, 藤井 輝久, 高田 清式, 山本 政弘, 宮川 寿一, 田邊 嘉也, 満屋 裕明, 岡 慎一 日本エイズ学会誌 15 (4) 375 -375 2013年11月 [査読無し][通常論文]
  • HIV感染者における梅毒血清反応と抗カルジオリピン抗体に関する検
    遠藤知之, 藤本勝也, 吉田美穂, 竹村龍, 杉田純一, 重松明男, 近藤健, 橋野聡, 田中淳司 日本エイズ学会誌 15 (2) 113 -118 2013年05月 [査読無し][通常論文]
  • 井端淳, 遠藤知之, 重松明男, 高畑むつみ, 安本篤史, 岡田耕平, 大庭幸治, 佐久嶋研, 西村千佳子, 佐藤典宏, 橋野聡, 豊嶋崇徳 日本造血細胞移植学会総会プログラム・抄録集 35th 228 2013年02月08日 [査読無し][通常論文]
  • T. Matsukawa, A. Shigematsu, K. Hayasaka, S. Fujisawa, S. Asanuma, A. Yasumoto, H. Goto, M. Takahata, T. Endo, J. Tanaka, S. Hashino, C. Shimizu, M. Imamura Bone Marrow Transplantation 47 (12) 1583 -1584 2012年12月 [査読無し][通常論文]
  • センテノ田村恵子, センテノ田村恵子, 坂本玲子, 坂本玲子, 江端あい, 江端あい, 加藤朋子, 富田健一, 渡部恵子, 遠藤知之, 佐藤典宏 日本エイズ学会誌 14 (4) 445 -445 2012年11月20日 [査読無し][通常論文]
  • 藤本勝也, 吉田美穂, 吉田美穂, 竹村龍, 竹村龍, 遠藤知之, 近藤健, 田中淳司, 橋野聡, 中西満, 中馬誠, 後藤了一, センテノ(田村, 恵子, センテノ(田村, 恵子, 渡部恵子, 大野稔子, 石田禎夫, 大竹孝明, 宮城島拓人, 小林一, 堤豊, 三宅高義, 北川浩彦, 佐藤典弘 日本エイズ学会誌 14 (4) 406 2012年11月20日 [査読無し][通常論文]
  • 遠藤知之, 遠藤知之, 藤本勝也, 藤本勝也, 吉田美穂, 吉田美穂, 吉田美穂, 竹村龍, 竹村龍, 竹村龍, 杉田純一, 杉田純一, 重松明男, 重松明男, 近藤健, 近藤健, 田中淳司, 田中淳司, 橋野聡, 佐藤典宏, 佐藤典宏 日本エイズ学会誌 14 (4) 391 -391 2012年11月20日 [査読無し][通常論文]
  • Mitsufumi Nishio, Satoshi Yamamoto, Tomoyuki Endo, Katsuya Fujimoto, Toshiya Sakai, Takeshi Kondo, Akio Shigematsu, Junichi Sugita, Satoshi Hashino, Junji Tanaka, Masahiro Imamura, Takanori Teshima BLOOD 120 (21) 2012年11月 [査読無し][通常論文]
  • 初回治療でアタザナビル/リトナビルを固定しエプジコムとツルバダを無作為割付するオープンラベル多施設臨床試験 ET study 96週結果
    西島 健, 高野 操, 石坂 美千代, 潟永 博之, 菊池 嘉, 遠藤 知之, 堀場 昌英, 金田 暁, 鯉渕 智彦, 内藤 俊夫, 吉田 正樹, 立川 夏夫, 横幕 能行, 藤井 輝久, 高田 清式, 山本 政弘, 松下 修三, 健山 正男, 田邊 嘉也, 満屋 裕明, 岡 慎一 日本エイズ学会誌 14 (4) 306 -306 2012年11月 [査読無し][通常論文]
  • 高橋健太, 松川敏大, 後藤秀樹, 遠藤知之, 橋野聡, 木村太一, 谷野美智枝, 西原広史, 田中伸哉, 田中伸哉 日本病理学会会誌 101 (1) 300 2012年03月26日 [査読無し][通常論文]
  • 石尾崇, 重松明男, 遠藤知之, 田中淳司, 坂井俊哉, 橋野聡, 山本聡, 今村雅寛 日本造血細胞移植学会総会プログラム・抄録集 34th 200 2012年02月01日 [査読無し][通常論文]
  • 松川敏大, 後藤秀樹, 遠藤知之, 重松明男, 高畑むつみ, 安本篤史, 浅沼真介, 橋野聡, 今村雅寛 日本造血細胞移植学会総会プログラム・抄録集 34th 244 2012年02月01日 [査読無し][通常論文]
  • 重松明男, 重松明男, 杉田純一, 高畑むつみ, 遠藤知之, 近藤健, 田中淳司, 橋野聡, 今村雅寛 日本造血細胞移植学会総会プログラム・抄録集 34th 226 2012年02月01日 [査読無し][通常論文]
  • 政氏伸夫, 田中淳司, 笠井正晴, 小笠原正浩, 小林直樹, 木山善雄, 杉田純一, 重松明男, 藤本勝也, 遠藤知之, 近藤健, 小林正伸, 今村雅寛 日本造血細胞移植学会総会プログラム・抄録集 34th 241 2012年02月01日 [査読無し][通常論文]
  • 高畑むつみ, 小野澤真弘, 橋野聡, 重松明男, 遠藤知之, 杉田純一, 藤本勝也, 近藤健, 田中淳司, 今村雅寛 日本造血細胞移植学会総会プログラム・抄録集 34th 295 2012年02月01日 [査読無し][通常論文]
  • 高橋 正二郎, 若狭 健太郎, 井端 淳, 重松 明男, 藤本 勝也, 遠藤 知之, 西尾 充史, 近藤 健, 田中 淳司, 橋野 聡, 浅香 正博, 今村 雅寛 無菌生物 = Japanese journal of germfree life and gnotobiology 41 (2) 106 -107 2011年12月01日 [査読無し][通常論文]
  • 遠藤知之, 藤本勝也, 後藤秀樹, 白鳥聡一, 杉田純一, 重松明男, 西尾充史, 近藤健, 田中淳司, 橋野聡, 今村雅寛, 佐藤典宏 日本エイズ学会誌 13 (4) 363 -363 2011年11月20日 [査読無し][通常論文]
  • Ritsuro Suzuki, Shinichi Kako, Rie Hyo, Koji Izutsu, Toshiro Ito, Katsuji Shinagawa, Tomoyuki Endo, Hisashi Sakamaki, Junji Suzumiya BLOOD 118 (21) 235 -235 2011年11月 [査読無し][通常論文]
  • Hideki Goto, Mitsufumi Nishio, Katsuya Fujimoto, Tomoyuki Endo, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hiroshi Nishihara, Takao Koike, Masahiro Imamura BLOOD 118 (21) 242 -243 2011年11月 [査読無し][通常論文]
  • HIV感染症の初回治療でアタザナビル/リトナビルを固定しエプジコムとツルバダを無作為割付するオープンラベル多施設臨床試験 ET study
    西島 健, 高野 操, 石坂 美千代, 潟永 博之, 菊池 嘉, 遠藤 知之, 堀場 昌英, 金田 暁, 藤井 毅, 内藤 俊夫, 吉田 正樹, 立川 夏夫, 横幕 能行, 藤井 輝久, 高田 清式, 山本 政弘, 松下 修三, 健山 正男, 田邊 嘉也, 満屋 裕明, 岡 慎一 日本エイズ学会誌 13 (4) 417 -417 2011年11月 [査読無し][通常論文]
  • 杉田 純一, 阿部 貴恵, 柏崎 晴彦, 小杉 瑞葉, 高橋 正二郎, 若狭 健太郎, 白鳥 聡一, 井端 淳, 庄野 雄介, 重松 明男, 小原 雅人, 藤本 勝也, 遠藤 知之, 西尾 充史, 近藤 健, 橋野 聡, 田中 淳司, 浅香 正博, 今村 雅寛 無菌生物 = Japanese journal of germfree life and gnotobiology 41 (1) 48 -53 2011年09月01日 [査読無し][通常論文]
  • 神田 真聡, 重松 明男, 岡田 耕平, 笠原 郁美, 岩崎 純子, 山口 圭介, 小野澤 真弘, 遠藤 知之, 秋沢 宏治, 石黒 信久, 橋野 聡, 今村 雅寛 臨床血液 52 (3) 118 -123 2011年03月30日 [査読無し][通常論文]
  • 笠原郁美, 小林直樹, 重松明男, 小原雅人, 西尾充史, 遠藤知之, 藤本勝也, 武田紫, 山口圭介, 杉田純一, 後藤秀樹, 近藤健, 太田秀一, 今井陽俊, 橋野聡, 田中淳司, 小池隆夫, 今村雅寛 日本造血細胞移植学会総会プログラム・抄録集 33rd 242 2011年 [査読無し][通常論文]
  • 岩崎純子, 岩崎純子, 岡田耕平, 岡田耕平, 笠原郁美, 笠原郁美, 山口圭介, 山口圭介, 重松明男, 重松明男, 小野澤真弘, 小野澤真弘, 遠藤知之, 遠藤知之, 柿木康孝, 橋野聡, 橋野聡, 小池隆夫, 今村雅寛, 今村雅寛, 浅香正博 日本エイズ学会誌 12 (4) 467 2010年11月20日 [査読無し][通常論文]
  • 遠藤知之, 後藤秀樹, 白鳥聡一, 渡部恵子, 杉田純一, 重松明男, 小原雅人, 藤本勝也, 西尾充史, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 佐藤典宏, 小池隆夫 日本エイズ学会誌 12 (4) 374 -374 2010年11月20日 [査読無し][通常論文]
  • 高橋正二郎, 高橋正二郎, 若狭健太郎, 若狭健太郎, 井端淳, 井端淳, 重松明男, 重松明男, 藤本勝也, 藤本勝也, 遠藤知之, 遠藤知之, 西尾充史, 西尾充史, 近藤健, 近藤健, 笠師久美子, 深井敏隆, 山田武広, 田中淳司, 田中淳司, 橋野聡, 橋野聡, 井関健, 小池隆夫, 浅香正博, 今村雅寛, 今村雅寛 臨床血液 51 (9) 999 2010年09月30日 [査読無し][通常論文]
  • 岡田耕平, 岡田耕平, 岩崎純子, 岩崎純子, 笠原郁美, 笠原郁美, 山口圭介, 山口圭介, 重松明男, 重松明男, 小野澤真弘, 小野澤真弘, 遠藤知之, 遠藤知之, 西尾充史, 西尾充史, 近藤健, 近藤健, 久保田康生, 笠師久美子, 深井敏隆, 田中淳司, 田中淳司, 橋野聡, 橋野聡, 井関健, 小池隆夫, 浅香正博, 今村雅寛, 今村雅寛 日本造血細胞移植学会総会プログラム・抄録集 32nd 248 2010年 [査読無し][通常論文]
  • 後藤秀樹, 西尾充史, 遠藤知之, 山本聡, 小原雅人, 山口圭介, 武田紫, 笠原郁美, 佐藤典宏, 小池隆夫 日本造血細胞移植学会総会プログラム・抄録集 32nd 243 2010年 [査読無し][通常論文]
  • 遠藤知之, 西尾充史, 山口圭介, 藤澤真一, 小野澤真弘, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 佐藤典宏, 小池隆夫 日本エイズ学会誌 11 (4) 507 -507 2009年11月20日 [査読無し][通常論文]
  • 山口圭介, 西尾充史, 坂井俊哉, 遠藤知之, 武田紫, 後藤秀樹, 笠原郁美, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 西原広史, 小池隆夫 臨床血液 50 (9) 944 2009年09月30日 [査読無し][通常論文]
  • 山本聡, 西尾充史, 遠藤知之, 武田紫, 山口圭介, 後藤秀樹, 笠原郁美, 佐藤典宏, 小池隆夫 臨床血液 50 (9) 1105 -1105 2009年09月30日 [査読無し][通常論文]
  • 在田幸太郎, 近藤健, 安本篤志, 杉田純一, 重松明男, 小野澤真弘, 遠藤知之, 西尾充史, 佐藤典宏, 橋野聡, 田中淳司, 今村雅寛 臨床血液 50 (9) 1094 -1094 2009年09月30日 [査読無し][通常論文]
  • 笠原郁美, 西尾充史, 遠藤知之, 武田紫, 山口圭介, 後藤秀樹, 佐藤典宏, 小池隆夫 臨床血液 50 (9) 1086 2009年09月30日 [査読無し][通常論文]
  • 遠藤知之, 藤澤真一, 西尾充史, 山本聡, 小原雅人, 橋野聡, 今村雅寛, 佐藤典宏, 小池隆夫 日本エイズ学会誌 10 (4) 456 -456 2008年11月20日 [査読無し][通常論文]
  • 髭修平, 中西満, 中馬誠, 堀本啓大, 小原俊央, 小野澤真弘, 加畑馨, 近藤健, 橋野聡, 田中淳司, 今村雅寛, 遠藤知之, 佐藤典宏, 小池隆夫, 渡部恵子, 大野稔子, 浅香正博 日本エイズ学会誌 10 (4) 411 -411 2008年11月20日 [査読無し][通常論文]
  • Mitsufumi Nishio, Kohki Kumano, Katsuya Fujimoto, Tomoyuki Endo, Satoshi Yamamoto, Akio Shigematsu, Takeshi Kondo, Junji Tanaka, Satoshi Hashino, Masahiro Imamura, Hiroshi Nishihara, Norihiro Sato, Takao Koike BLOOD 112 (11) 525 -525 2008年11月 [査読無し][通常論文]
  • Mitsufumi Nisino, Tomoyuki Endo, Katsuya Fujimoto, Satoshi Yamamoto, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Ikumi Kasahara, Norihiro Sato, Takao Koike BLOOD 112 (11) 1115 -1115 2008年11月 [査読無し][通常論文]
  • 重松明男, 重松明男, 杉田純一, 杉田純一, 山本聡, 山本聡, 岡田耕平, 岡田耕平, 小野澤真弘, 小野澤真弘, 加畑馨, 加畑馨, 遠藤知之, 遠藤知之, 安本篤史, 安本篤史, 高畑むつみ, 高畑むつみ, 西尾充史, 西尾充史, 近藤健, 近藤健, 橋野聡, 橋野聡, 田中淳司, 田中淳司, 小池隆夫, 浅香正博, 今村雅寛, 今村雅寛 臨床血液 49 (9) 874 2008年09月30日 [査読無し][通常論文]
  • 熊野弘毅, 西尾充史, 藤本勝也, 西原広史, 遠藤知之, 山本聡, 坂井俊哉, 小原雅人, 田中伸哉, 佐藤典宏, 小池隆夫 臨床血液 49 (9) 1194 -1194 2008年09月30日 [査読無し][通常論文]
  • 後藤秀樹, 西尾充史, 遠藤知之, 山本聡, 小原雅人, 山口圭介, 武田紫, 笠原郁美, 佐藤典宏, 小池隆夫 臨床血液 49 (9) 870 -870 2008年09月30日 [査読無し][通常論文]
  • 西尾充史, 遠藤知之, 山本聡, 重松明男, 小原雅人, 山口圭介, 武田紫, 後藤秀樹, 笠原郁美, 佐藤典宏, 橋野聡, 近藤健, 加畑馨, 小野澤真弘, 田中淳司, 今村雅寛, 浅香正博, 小池隆夫 臨床血液 49 (9) 1172 -1172 2008年09月30日 [査読無し][通常論文]
  • 重松 明男, 杉田 純一, 山本 聡, 小野澤 真弘, 遠藤 知之, 加畑 馨, 白鳥 聡一, 若狭 健太郎, 高畑 むつみ, 近藤 健, 田中 淳司, 西尾 充史, 橋野 聡, 小池 隆夫, 浅香 正博, 今村 雅寛 無菌生物 = Japanese journal of germfree life and gnotobiology 38 (1) 27 -32 2008年09月01日 [査読無し][通常論文]
  • M. Nishio, T. Endo, S. Nakao, N. Sato, T. Koike INTERNATIONAL JOURNAL OF CARDIOLOGY 127 (3) 400 -401 2008年07月 [査読無し][通常論文]
     
    A 30-year-old Japanese woman with acquired severe aplastic anemia (SAA), diagnosed 20 years ago, was referred to our institution for allogeneic stem cell transplantation (SCT). As an unusual case of long-standing SAA, the patient was complicated with moderate heart failure due to secondary hemochromatosis. After successful SCT using a non-myeloablative conditioning regimen, she needed no transfusion. Five years after SCT, echocardiography showed a dramatic improvement of her cardiac function. This case indicates that the cardiac function in secondary hemochromatosis could be reversed once iron overload from multitransfusions is stopped. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
  • 安本篤志, 重松明男, 近藤健, 山本聡, 杉田純一, 小野澤真宏, 遠藤知之, 高畑むつみ, 田中淳司, 橋野聡, 西尾充史, 小池隆夫, 浅香正博, 今村雅寛 日本リンパ網内系学会会誌 48 107 2008年05月09日 [査読無し][通常論文]
  • 遠藤知之, 藤本勝也, 山本聡, 西尾充史, 渡辺直也, 眞島任史, 佐藤典宏, 小池隆夫 日本エイズ学会誌 9 (4) 517 -517 2007年11月20日 [査読無し][通常論文]
  • Davorka Messmer, Hsu-Hsiang Chang, Tomoyuki Endo, Thomas J. Kipps BLOOD 110 (11) 345A -345A 2007年11月 [査読無し][通常論文]
  • 山本聡, 西尾充史, 遠藤知之, 藤本勝也, 坂井俊哉, 小原雅人, 熊野弘毅, 武田紫, 山口圭介, 後藤秀樹, 佐藤典宏, 小池隆夫 臨床血液 48 (9) 1132 -1132 2007年09月30日 [査読無し][通常論文]
  • 非ホジキンリンパ腫に対するリツキシマブ併用自家移植後の免疫グロブリン値とFCGR3Aの遺伝子多型
    西尾 充史, 遠藤 知之, 藤本 勝也, 山本 聡, 坂井 俊哉, 熊野 弘毅, 小原 雅人, 山口 圭介, 武田 紫, 後藤 秀樹, 佐藤 典宏, 堀田 哲也, 中川 久子, 小池 隆夫 臨床血液 48 (9) 980 -980 2007年09月 [査読無し][通常論文]
  • Masahiko Shigemura, Takanori Moriyama, Hitoshi Shibuya, Masato Obara, Tomoyuki Endo, Satoshi Hashino, Hiroshi Yokouchi, Masahiro Asaka, Chikara Shimizu, Hitoshi Chiba, Masaharu Nishimura CLINICA CHIMICA ACTA 380 (1-2) 254 -254 2007年05月 [査読無し][通常論文]
  • Jerry X. Liu, Tomoyuki Endo, Thomas J. Kipps, Carson A. Dennis, Lu Desheng BLOOD 108 (11) 595A -595A 2006年11月 [査読無し][通常論文]
  • Davorka Messmer, Tomoyuki Endo, Bradley T. Messmer, Thomas J. Kipps BLOOD 108 (11) 177A -177A 2006年11月 [査読無し][通常論文]
  • M Nishio, T Endo, K Fujimoto, N Sato, T Sakai, M Obara, K Kumano, K Minauchi, T Koike EUROPEAN JOURNAL OF HAEMATOLOGY 76 (1) 91 -91 2006年01月 [査読無し][通常論文]
  • 乃村 俊史, 阿部 理一郎, 藤本 勝也, 遠藤 知之, 小池 隆夫, 清水 宏 日本皮膚科学会雑誌 = THE JAPANESE JOURNAL OF DERMATOLOGY 115 (13) 2236 -2238 2005年12月 [査読無し][通常論文]
  • T Endo, M Nishio, T Fukuda, HB Cottam, SL Kalled, TJ Kipps BLOOD 106 (11) 56A -56A 2005年11月 [査読無し][通常論文]
  • 小原雅人, 重村雅彦, 遠藤知之, 山口圭介, 武田紫, 山倉昌之, 皆内康一郎, 熊野弘毅, 坂井俊哉, 藤本勝也, 山本聡, 西尾充史, 佐藤典宏, 小池隆夫 臨床血液 46 (8) 868 2005年08月30日 [査読無し][通常論文]
  • T Endo, M Nishio, L Rassenti, AP Kater, TJ Kipps BLOOD 104 (11) 284B -284B 2004年11月 [査読無し][通常論文]
  • 当科における進行期follicular lymphomaに対する自家末梢血幹細胞移植併用超大量化学療法の治療成績
    藤本 勝也, 山倉 昌之, 皆内 康一郎, 小原 雅人, 熊野 弘毅, 坂井 俊哉, 遠藤 知之, 西尾 充史, 佐藤 典宏, 高島 英典, 能登谷 京, 向井 正也, 小池 隆夫 日本血液学会・日本臨床血液学会総会プログラム・抄録集 66回・46回 798 -798 2004年09月 [査読無し][通常論文]
  • 皆内康一郎, 遠藤知之, 山倉昌之, 小原雅人, 熊野弘毅, 坂井俊哉, 佐藤典宏, 高見昭良, 中尾真二 臨床血液 45 (8) 901 2004年08月30日 [査読無し][通常論文]
  • 藤本勝也, 皆内康一郎, 小原雅人, 熊野弘毅, 坂井俊哉, 遠藤知之, 小泉和輝, 小池隆夫, 佐藤典宏 日本輸血学会雑誌 50 (1) 145 -145 2004年03月31日 [査読無し][通常論文]
  • H Fukaya, WG Xiao, K Inaba, Y Suzuki, M Hirokawa, Y Kawabata, A Komatsuda, T Endo, G Takada, K Sawada BLOOD 102 (11) 141B -141B 2003年11月 [査読無し][通常論文]
  • 遠藤知之, 小原雅人, 熊野弘毅, 坂井俊哉, 藤本勝也, 茂木祐子, 佐藤典宏, 池田久実, 小池隆夫 臨床血液 44 (8) 802 -802 2003年08月30日 [査読無し][通常論文]
  • 藤本勝也, 小原雅人, 熊野弘毅, 坂井俊哉, 遠藤知之, 小泉和輝, 佐藤典宏, 小池隆夫 臨床血液 44 (8) 765 -765 2003年08月30日 [査読無し][通常論文]
  • 熊野弘毅, 小原雅人, 坂井俊哉, 藤本勝也, 遠藤知之, 小泉和輝, 矢口裕章, 佐藤典宏, 小池隆夫 臨床血液 44 (8) 817 2003年08月30日 [査読無し][通常論文]
  • WG Xiao, K Koizumi, M Nishio, T Endo, T Koike, K Sawada BLOOD 100 (11) 169B -170B 2002年11月 [査読無し][通常論文]
  • 非ホジキンリンパ腫に対する自家末梢血幹細胞移植併用超大量化学療法後の二次性MDSと染色体異常
    藤本 勝也, 坂井 俊哉, 山本 聡, 遠藤 知之, 西尾 充史, 小泉 和輝, 小池 隆夫, 澤田 賢一, 河野 通史, 大西 勝憲, 佐藤 典宏, 池田 久實 臨床血液 43 (8) 420 -420 2002年08月 [査読無し][通常論文]
  • 自家末梢血CD34陽性細胞選択移植後の免疫低下状態に対するin vitro増幅自己活性化Tリンパ球輸注
    遠藤 知之, 東 寛, 坂井 俊哉, 藤本 勝也, 山本 聡, 西尾 充史, 小泉 和輝, 佐藤 典宏, 池田 久實, 澤田 賢一, 小池 隆夫 臨床血液 43 (8) 450 -450 2002年08月 [査読無し][通常論文]
  • M Nishio, S Nakao, T Endo, K Fujimoto, H Takashima, T Sakai, A Bacigalupo, T Koike, K Sawada BONE MARROW TRANSPLANTATION 28 (8) 783 -785 2001年10月 [査読無し][通常論文]
     
    A 30-year-old Japanese woman weighing 35 kg with severe hemochromatosis due to multiple transfusions was referred to our clinic for treatment of severe aplastic anemia (SAA). The patient had heart failure with an ejection fraction of 36% requiring diuretics and a severe liver dysfunction with an indocyanine green clearance rate of 18%, as well as other transfusion-related complications such as chronic hepatitis due to hepatitis C virus and diabetes mellitus. She was treated with a non-myeloablative preparative regimen that included fludarabine monophosphate (Flu, 120 mg/m(2)), cyclophosphamide (CY, 1200 mg/m(2)) and antithymocyte globulin (ATG, 15 mg/kg) followed by allogeneic peripheral blood stem cell transplantation (PBSCT) from her HLA-matched sister. The regimen was well tolerated, and engraftment rapidly occurred without any therapy-related complications. Chimerism analysis on day 14 after transplant showed reconstitution with 100% donor cells. She no longer needed transfusion after day 23 and has been well in 90% Karnofsky status at 4 months post transplant. The clinical course of this patient indicates that this preparative regimen enables SAA patients with severe organ failure to safely undergo allogeneic stem cell transplantation.
  • M Nishio, K Koizumi, T Endo, K Fujimoto, T Koike, K Sawada HAEMATOLOGICA 86 (6) 667 -668 2001年06月 [査読無し][通常論文]
  • T Endo, A Oda, Y Haseyama, M Nishio, K Koizumi, Sato, I, Y Amasaki, Y Sato, K Ikebuchi, H Ikeda, T Koike, KI Sawada BLOOD 96 (11) 80A -80A 2000年11月 [査読無し][通常論文]
  • 遠藤 知之, 澤田 賢一, 藤本 勝也, 山本 聡, 高島 英典, 長谷山 美仁, 西尾 充史, 小泉 和輝, 小池 隆夫 臨床血液 41 (8) 681 -686 2000年08月30日 [査読無し][通常論文]
  • 遠藤 知之, 澤田 賢一, 藤本 勝也, 山本 聡, 高島 英典, 長谷山 美仁, 西尾 充史, 小泉 和輝, 小池 隆夫 臨床血液 41 (4) 322 -328 2000年04月30日 [査読無し][通常論文]
  • H Hashimoto, K Sawada, K Koizumi, M Nishio, T Endo, T Takashima, H Kobayashi, T Koike BONE MARROW TRANSPLANTATION 24 (12) 1369 -1371 1999年12月 [査読無し][通常論文]
  • 西尾充史, 沢田賢一, 藤本勝也, 山本聡, 遠藤知之, 高橋英典, 橋本英明, 佐藤典宏, 池田久実 日本輸血学会雑誌 45 (6) 952 -953 1999年12月01日 [査読無し][通常論文]
  • K Koizumi, M Nishio, H Hashimoto, T Endo, H Takashima, Y Haseyama, N Sato, T Yasukouchi, T Koike, K Sawada BLOOD 94 (10) 352B -352B 1999年11月 [査読無し][通常論文]
  • M Nishio, A Oda, K Koizumi, Satoh, I, Y Haseyama, T Endo, H Takashima, H Hashimoto, M Fujihara, K Ikebuchi, H Ikeda, T Koike, K Sawada BLOOD 94 (10) 264A -264A 1999年11月 [査読無し][通常論文]
  • 自家末梢血CD34陽性細胞選択移植を施行した悪性リンパ腫の3症例
    小泉 和輝, 澤田 賢一, 遠藤 知之, 高島 英典, 橋本 英明, 西尾 充史, 西尾 仁, 高野 弥奈, 安河内 太郎, 佐藤 典宏 International Journal of Hematology 69 (Suppl.1) 216 -216 1999年04月 [査読無し][通常論文]
  • 西尾 充史, 澤田 賢一, 小泉 和輝, 遠藤 知之, 高島 英典, 橋本 英明, 長谷山 美仁, 片桐 江理, 深田 嘉一, 高野 弥奈, 垂水 隆志, 安河内 太郎, 小池 隆夫 臨床血液 39 (8) 580 -585 1998年08月30日 [査読無し][通常論文]

教育活動情報

主要な担当授業

  • 医学総論
    開講年度 : 2019年
    課程区分 : 博士後期課程
    開講学部 : 医学研究科
  • 基本医学研究
    開講年度 : 2019年
    課程区分 : 修士課程
    開講学部 : 医学院
    キーワード : 白血病、骨髄異形成症候群、リンパ腫、多発性骨髄腫、化学療法、分子標的療法、造血幹細胞移植、移植片対宿主病、移植片対腫瘍効果 leukemia, myelodysplastic syndrome, malignant lymphoma, multiple myeloma, chemotherapy, molecular targeting therapy, hematopoietic stem cell transplantation, graft versus host disease, graft versus tumor effect
  • 基本医学総論
    開講年度 : 2019年
    課程区分 : 修士課程
    開講学部 : 医学院
    キーワード : 造血、造血機構、血球分化、白血病、リンパ腫、造血不全、がんプロフェショナル hematopoiesis, hematopoietic system, hematopoietic differentiation, leukemia, malignant lymphoma, bone marrow failure, human resource development for cancer
  • 医学総論
    開講年度 : 2019年
    課程区分 : 博士後期課程
    開講学部 : 医学院
    キーワード : 造血、造血機構、血球分化、白血病、リンパ腫、造血不全、がんプロフェショナル hematopoiesis, hematopoietic system, hematopoietic differentiation, leukemia, malignant lymphoma, bone marrow failure, human resource development for cancer
  • 基盤医学研究
    開講年度 : 2019年
    課程区分 : 博士後期課程
    開講学部 : 医学院
    キーワード : 造血器悪性腫瘍、造血器難治性疾患、病態、診断、治療、造血幹細胞移植、化学療法、抗体療法、分子標的療法、移植片対宿主病、移植片対白血病、再生医療 hematological malignancy, hematological refractory disease, pathogenesis, diagnosis, treatment, hematopoietic stem cell transplantation, chemotherapy, antibody therapy, molecular targeting therapy, graft versus host disease, graft versus leukemia effect, regenerative medicine
  • 臨床医学研究
    開講年度 : 2019年
    課程区分 : 博士後期課程
    開講学部 : 医学院
    キーワード : 造血器悪性腫瘍、造血器難治性疾患、病態、診断、治療、造血幹細胞移植、化学療法、抗体療法、分子標的療法、移植片対宿主病、移植片対白血病、再生医療 hematological malignancy, hematological refractory disease, pathogenesis, diagnosis, treatment, hematopoietic stem cell transplantation, chemotherapy, antibody therapy, molecular targeting therapy, graft versus host disease, graft versus leukemia effect, regenerative medicine
  • 統合・血液学
    開講年度 : 2019年
    課程区分 : 学士課程
    開講学部 : 医学部
    キーワード : 造血、造血機構、血球分化、白血病、リンパ腫、造血不全、がんプロフェショナル


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.